



(86) **Date de dépôt PCT/PCT Filing Date:** 2014/05/08
(87) **Date publication PCT/PCT Publication Date:** 2015/04/30
(85) **Entrée phase nationale/National Entry:** 2016/06/27
(86) **N° demande PCT/PCT Application No.:** KR 2014/004107
(87) **N° publication PCT/PCT Publication No.:** 2015/060511
(30) **Priorité/Priority:** 2013/10/22 (KR10-2013-0125675)

(51) **Cl.Int./Int.Cl.** *G06F 19/10* (2011.01),
C12N 15/11 (2006.01), *C12Q 1/68* (2006.01),
G01N 33/50 (2006.01)
(71) **Demandeur/Applicant:**
KIM, SUNG-CHUN, KR
(72) **Inventeur/Inventor:**
KIM, SUNG-CHUN, KR
(74) **Agent:** GOWLING WLG (CANADA) LLP

(54) **Titre : MARQUEUR POUR GENERER DES INFORMATIONS DE LIAISON SUR DES BIOMOLECULES ET DES ACIDES NUCLEIQUES, PROCEDE DE PREPARATION AFFECTANT, ET PROCEDE ET APPAREIL D'ANALYSE DE BIOMOLECULE LES UTILISANT**
(54) **Title: MARKER FOR GENERATING BINDING INFORMATION ON BIOMOLECULES AND NUCLEIC ACIDS, PREPARATION METHOD THEREFOR, AND METHOD AND APPARATUS FOR ANALYZING BIOMOLECULE BY USING SAME**




Figure 8

(57) **Abrégé/Abstract:**

The present invention relates to: a reference substance and a nucleic acid chip for generating binding information on biomolecules and analysis single-stranded nucleic acids in a biosample composed of biomolecules; a preparation method therefor; and a method for analyzing biomolecules by using the same, and the reference substance and the nucleic acid chip can be used for analyzing the biological meaning of the biomolecules. In addition, the present invention relates to: a method for preparing an external marker and a biochip for generating the binding information of biomolecules and ligands; and a method for analyzing biomolecules by using the same. The external marker and the biochip of the present invention can be used in the field of analyzing the biological meaning of the biomolecules.



(12) 특허협력조약에 의하여 공개된 국제출원

(19) 세계지식재산권기구
국제사무국(43) 국제공개일
2015 년 4 월 30 일 (30.04.2015)(10) 국제공개번호
WO 2015/060511 A1

- (51) 국제특허분류:
G06F 19/10 (2011.01) C12N 15/11 (2006.01)
C12Q 1/68 (2006.01) G01N 33/50 (2006.01)
- (21) 국제출원번호: PCT/KR2014/004107
- (22) 국제출원일: 2014 년 5 월 8 일 (08.05.2014)
- (25) 출원언어: 한국어
- (26) 공개언어: 한국어
- (30) 우선권정보:
10-2013-0125675 2013 년 10 월 22 일 (22.10.2013) KR
- (71) 출원인: 주식회사 바이오이즈 (BIOIS CORP.)
[KR/KR]; 152-777 서울시 구로구 디지털로 32 길 30,
703 호, Seoul (KR).
- (72) 발명자: 김성천 (KIM, Sung-Chun); 120-080 서울시 서
대문구 독립문공원길 17, 110 동 202 호, Seoul (KR).
- (74) 대리인: 위병갑 (WIE, Byoung-Gap); 137-873 서울시
서초구 반포대로 26 길 21 소소헌빌딩 1 층, Seoul (KR).
- (81) 지정국 (별도의 표시가 없는 한, 가능한 모든 종류의
국내 권리의 보호를 위하여): AE, AG, AL, AM, AO,

AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KZ, LA,
LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK,
MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA,
PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD,
SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


- (84) 지정국 (별도의 표시가 없는 한, 가능한 모든 종류의
역내 권리의 보호를 위하여): ARIPO (BW, GH, GM,
KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG,
ZM, ZW), 유라시아 (AM, AZ, BY, KG, KZ, RU, TJ,
TM), 유럽 (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC,
MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR),
OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM,
ML, MR, NE, SN, TD, TG).

공개:

- 국제조사보고서와 함께 (조약 제 21 조(3))

(54) Title: MARKER FOR GENERATING BINDING INFORMATION ON BIOMOLECULES AND NUCLEIC ACIDS, PRE-
PARATION METHOD THEREFOR, AND METHOD AND APPARATUS FOR ANALYZING BIOMOLECULE BY USING
SAME

(54) 발명의 명칭 : 생체분자와 핵산의 결합정보를 생성하기 위한 마커, 이의 제조방법, 이를 이용한 생체분자 분석방법
및 장치



AA ... Blood collection
BB ... Scanner interface (interlocked with OCS system)
CC ... AptaCDSS DB Server / Store sample information of patient / Store analysis
result of diagnosis engine
DD ... Disease analysis system / Diagnose and analyse diseases by using artificial
intelligence (NN, DT, BN, SVM)
EE ... Diagnosis of doctor
FF ... Result output and analysis / Suggest various analysis results / Interlocked with
OCS system

(57) Abstract: The present invention relates to:
a reference substance and a nucleic acid chip for
generating binding information on biomolecules
and analysis single-stranded nucleic acids in a
biosample composed of biomolecules; a prepar-
ation method therefor; and a method for analyz-
ing biomolecules by using the same, and the ref-
erence substance and the nucleic acid chip can
be used for analyzing the biological meaning of
the biomolecules. In addition, the present inven-
tion relates to: a method for preparing an external
marker and a biochip for generating the bind-
ing information of biomolecules and ligands;
and a method for analyzing biomolecules by us-
ing the same. The external marker and the bio-
chip of the present invention can be used in the
field of analyzing the biological meaning of the
biomolecules.

(57) 요약서: 본 발명은 생체분자들로 구성된
생체시료에 있는 생체분자들과 분석단일가
닥핵산의 결합정보 생성을 위한 기준물질
및 핵산

[다음 쪽 계속]

WO 2015/060511 A1

칩, 이의 제조방법 및 이들을 이용한 생체분자 분석방법에 관한 것으로, 기준물질 및 핵산 칩은 생체분자들의 생물학적 의미를 분석하는 것에 사용될 수 있다. 또한 본 발명은 생체분자와 리간드의 결합정보를 생성하기 위한 외부마커와 바이오칩의 제조방법 및 이들을 이용한 생체분자 분석방법에 관한 것이다, 본 발명의 외부마커 및 바이오칩은 생체분자들의 생물학적 의미를 분석하는 분야에 사용될 수 있다.

DESCRIPTION

**MARKER FOR GENERATING BINDING INFORMATION ON BIOMOLECULES AND
NUCLEIC ACIDS, PREPARATION METHOD THEREFOR, AND METHOD AND
5 APPARATUS FOR ANALYZING BIOMOLECULE BY USING SAME**

Technical Field

The present invention relates, in general, to a reference substance and a nucleic acid chip for predicting biological
10 significance of biomolecules in a biosample composed of biomolecules, a method for preparing the same, and a method and an apparatus for analyzing biomolecules using the same. In addition, the present invention relates, in general, to a method for preparing an external marker (that is, external
15 reference substance) and a biochip for generating binding information on biomolecules and ligands, and a method for analyzing biomolecules using the same.

Background Art

20 In accordance with advances in physics, biochemistry, and bioinformatics, many technologies for obtaining profiles of a large number of biomolecules (proteins and carbohydrates) constituting a biosample have been developed. However, in spite of such technologies, there is a considerable need for
25 novel and efficient methods and apparatuses due to problems

regarding the use, maintenance cost, feasibility, accuracy, sensitivity, required testing times, and process automation ability of the existing methods or devices.

A method for generating comprehensive information on
5 quantitative states of these biomolecules, that is, a profile
of the biomolecules in the biosample containing the
biomolecules, which is not an ultimate object but is a means
for achieving the object, may be usefully used to identify
microorganisms, cells, tissues, and the like, such that the
10 method for generating a profile has been widely applied to
medicine, veterinary medicine, environmental engineering, food
engineering, agriculture, and the like.

A clinical decision support system for analyzing
biological significance using the profile of the biomolecules
15 in a biosample is a system for supporting a decision making
process by a doctor, associated with diagnosis and treatment of
a patient. The clinical decision support system is largely
divided into a case-based machine learning inference system and
an expert system. The case-based machine learning inference
20 system is a system of collecting clinical information of
patients with diagnosed diseases and biological information,
that is, profile data on the biomolecules, and then inferring
or determining a disease on the basis of given clinical
information, biological information, and the like, using
25 machine learning. The expert system is a system of diagnosing

a disease using a rule predetermined by a medical expert.

A nucleic acid is a linear multimer in which nucleotides are linked by covalent bonds, wherein the nucleotide is a small organic compound composed of a phosphoric acid, a sugar, and a
5 purine (adenine or guanine) or a pyrimidine (cytosine, thymine, or uracil). The nucleic acid exists in single-stranded form or double-stranded form, and a single-stranded nucleic acid forms a unique stereoscopic structure by hydrogen bonds and interactions between the nucleotides under specific physical
10 conditions, and this stereoscopic structure is determined by a base sequence of the single strand.

In general, nucleic acids such as deoxyribonucleic acids (DNAs) and ribonucleic acids (RNAs) are information storage molecules for expression of proteins serving as components of
15 cell structures or having activities such as enzymes, and the like. Since it was reported in 1982 that RNA can also have an enzyme activity by formation of a specific structure, many reports on structural characteristics of the nucleic acids and specific functions depending on the structural characteristics
20 have been reported.

Nucleic acid consists of repeating units of four bases to form various stereoscopic structures with high diversity, and the nucleic acids form complexes through interaction with specific substances, such that this stereoscopic structure is
25 stabilized.

Since nucleic acid may serve as a single-stranded nucleic acid (ligand) for molecules including proteins, nucleic acids binding to specific substances with high binding affinity and specificity are selected from a combinatorial library of
5 single-stranded nucleic acids arranged in various base sequences through a predetermined selection process and through a base sequencing process.

A method for selecting a nucleic acid binding to a specific substance is referred to as systematic evolution of
10 ligand by exponential enrichment (SELEX), and the selected nucleic acid is referred to as an aptamer (Tuerk C. and Gold L.; Science, 249, pp505-510, 1990).

Nucleic acids (aptamers) capable of binding to various biomolecules, such as proteins capable of binding to nucleic
15 acids in a natural state, or proteins that do not bind to the nucleic acids, have been selected through the SELEX as described above.

However, a method for selecting a nucleic acid through the existing SELEX is a method for selecting a nucleic acid
20 (aptamer) having high binding affinity by preferentially mass-producing and purifying a corresponding protein (specific substance) prior to selection of a nucleic acid specifically binding to the specific substance (for example, the protein), reacting a library of single-stranded nucleic acids with the
25 produced protein, and repeating selection and amplification.

In this method, first, it was essential to secure the specific substance for selecting the nucleic acid. Therefore, in the method for selecting a nucleic acid through the SELEX according to the related art, a technical idea of selecting and using
5 nucleic acids as a group having significance in a group of numerous unknown biomolecules contained in the biosample was not recognized. Biomolecule-single-stranded nucleic acid complexes may be selected by various methods. For example, a method for fixing the biomolecule to harvest a complex, and
10 washing the complex, a capillary electrophoresis method, and the like, may be used.

Profiles of biomolecules including unknown molecules constituting tissues, cell mass, cells, microorganisms, and the like, which are biosamples, have been made by various methods
15 using physical and chemical properties thereof. In general, a profile of biomolecules, which is a quantitative state of the biomolecules, in the biosample has been confirmed by performing electrophoresis on the biomolecules using molecular weights or pI values thereof.

20 In addition, a method for analyzing a profile to determine useful biomolecules, separating the useful biomolecules, and confirming constituent ingredients of the separated biomolecules using matrix assisted laser desorption/ionization-time spectroscopy of flight (MALDI-TOF), or the like, has been
25 performed. Recently, various research into protein profiles

has been conducted by surface-enhanced laser desorption/ionization time of flight mass spectrometry (SELDI-TOFMS) (Adam et al., Cancer Research, 62, 3609-3614. 2002; Li et al., Clinical Chemistry, 48, 1296-1304. 2002; and Petricoin et al., The Lancet, 359,572-577. 2002).

Also recently, protein chips or aptamer chips have been developed and used by a high throughput screening method for proteomes (Smith et al., Mol. Cell Proteomics, 11-18. 2003; and McCauley et al., Anal. Biochem., 319(2), 244-250. 2003). As a supporter used in the high throughput screening method as described above, there are a glass slide, a sensing surface of a biosensor, beads, nanoparticles, and the like.

Since arrangement of an antibody on a protein chip is known, the protein chip may be used to identify and quantify a specific substance. As a method for preparing a protein chip, there is a method of spotting an antibody to fix the antibody using a microarrayer. A protein chip sensing technology should be able to sense signals generated at very weak intensities in a state the protein chip is designed to integrate various antibodies at a high density on a small area in order to provide as much information as possible with one chip. Further, as bio-information of proteins is expanding, a degree of integration of the protein chip is also increasing, such that a novel method capable of rapidly and accurately quantitatively detecting a protein is required.

As a detection method, laser induced fluorescence spectroscopy has been mainly used up to now, and an electrochemical detection method, or the like, has been developed. A method for generating and analyzing a profile of specific proteins in a biosample using a protein chip has been developed through various processes as described above, but there are problems in that expensive apparatuses and reagents are used, and complicated procedures should be performed, etc., and there is a limitation in that the protein chip is applicable only to antigenic molecules.

An aptamer chip is different from the protein chip in that an aptamer (nucleic acid) is used instead of the antibody in the protein chip, and other factors of the aptamer chip are significantly similar to those of the protein chip.

As described above, methods for generating a quantitative state, that is, a profile, of biomolecules in a biosample using the protein chip and the aptamer chip have been developed, but there are problems in that expensive apparatuses and reagents are used, and complicated procedures should be performed, and the like. Particularly, there is a limitation in that protein chips or aptamer chips may be restrictively prepared only with respect to already known proteins from which antibodies or aptamers may be prepared.

Although a biosample is known to be composed of millions of proteins, only tens of thousands of proteins are identified.

Therefore, there is a considerable need for a technology of generating a quantitative state, that is, a profile of unknown biomolecules such as unknown proteins in a biosample.

The present inventor suggested reverse-SELEX for
5 generating a profile for proteome (see Korean Patent No. 10-0670799), an aptamer-based nucleic acid chip (see Korean Patent No. 10-0464225), a method for analyzing biological significance using an aptamer-based nucleic acid chip (see Korean Patent No. 10-0923048), and the like, but there were problems in that a
10 suitable reference substance and a quality control method at the time of high throughput screening in order to generate proteome profiles were not suggested, and thus, it is impossible to perform suitable quality control upon generating and analyzing the profile. Therefore, the present invention
15 was suggested in order to solve the problems as described above.

In research into a technology capable of entirely analyzing biomolecules in a biosample, analysis of profiles of biomolecules medically associated with diseases may be used to identify biomolecules that can serve as diagnostic markers, can
20 be used to monitor therapeutic results, can play important roles in the outbreak or the progressions of diseases, are related to disease sensitivity, and can become target molecules for novel drug development.

25 **Disclosure**

Technical Problem

Accordingly, the present invention has been made keeping in mind the above problems occurring in the related art, and the present invention is intended to propose a reference
5 substance and a nucleic acid chip for generating binding information on biomolecules and analysis single-stranded nucleic acids in a biosample composed of two or more biomolecules while performing internal quality control, a method for preparing the same, and a method and an apparatus
10 for analyzing biomolecules using the same, such that various biological significance including disease information associated with the biomolecules may be analyzed from the binding information efficiently formed using the same.

In addition, the present invention is intended to propose
15 an external reference substance and a biochip capable of generating binding information on biomolecules contained in a biosample and ligands, such that biological significance including disease information associated with the biomolecules may be analyzed from the binding information efficiently formed
20 using the same.

Technical Solution

In order to achieve the above object, according to one aspect of the present invention, there is provided a method for
25 analyzing a biomolecule by an analysis single-stranded nucleic

acid, wherein a quality control reference substance for analyzing an analysis single-stranded nucleic acid binding to biomolecules in a biosample composed of two or more biomolecules is used, and the binding single-stranded nucleic acid is selected from a nucleic acid library composed of random single-stranded nucleic acids having random base sequences, whereby internal quality control is performed by analyzing a quality control single-stranded nucleic acid using a nucleic acid analysis method.

10 According to another aspect of the present invention, there is provided a nucleic acid chip, wherein capture probes synthesized using base sequences of a binding single-stranded nucleic acid and a quality control single-stranded nucleic acid are affixed onto a supporter, and binding information on the binding single-stranded nucleic acid and the quality control single-stranded nucleic acid for selecting an analysis single-stranded nucleic acid is formed.

According to another aspect of the present invention, there is provided a method for analyzing biomolecules, wherein a quality control reference substance for analyzing biomolecules in a biosample using an analysis single-stranded nucleic acid is used, and internal quality control is performed by analyzing a quality control single-stranded nucleic acid using a nucleic acid analysis method.

25 According to another aspect of the present invention,

there is provided a method for analyzing biomolecules, wherein a protein chip is analyzed using a target probe prepared by mixing an analysis target probe and a comparison target probe with each other, the analysis target probe being prepared by
5 reacting an analysis single-stranded nucleic acid with biomolecules in a biosample and a comparison target probe being prepared by reacting the analysis single-stranded nucleic acid with biomolecules in a control biosample.

According to another aspect of the present invention,
10 there is provided a nucleic acid chip, wherein capture probes prepared using base sequences of analysis single-stranded nucleic acids and quality control single-stranded nucleic acids are affixed onto a support, and the nucleic acid chip is used to generate binding information on biomolecules and the
15 analysis single-stranded nucleic acids for analyzing biological significance of the biomolecules in the biosample.

According to another aspect of the present invention, there is provided a reference substance, wherein the reference substance is composed of external molecules that are not
20 contained in a biosample, and used for quality control of an analysis process for analyzing biological significance of biomolecules in the biosample as an analysis single-stranded nucleic acid, and for quantitative analysis of the biomolecules contained in the biosample.

25 According to another aspect of the present invention,

there is provided a kit for analyzing biomolecules, wherein the analysis single-stranded nucleic acid and the reference substance for analyzing biological significance of the biomolecules in the biosample are used.

5 According to another aspect of the present invention, there is provided an apparatus for analyzing biomolecules, wherein the biomolecules are analyzed by a method for analyzing biomolecules using an analysis single-stranded nucleic acid and a reference substance, and it has a system for analyzing
10 biomolecules, including a sample treating device for preparing biomolecules in the biosample and an amplification device composed a module for preparing and amplifying a biomolecule-single-stranded nucleic acid complex and a module for analyzing the amplified product.

15

Advantageous Effects

With a reference substance and a nucleic acid chip according to the present invention, and a method for analyzing biomolecules in a biosample composed of two or more
20 biomolecules using the same, it is possible to generate profiles of biomolecules contained in biosamples including microorganisms, cells, and proteins using a significantly simple, cheap, and efficient method and apparatus based on high throughput screening, and thus, the reference substance, the
25 nucleic acid chip, and the method and the apparatus for

analyzing biomolecules may be applied as useful tools for analyzing biological significance of the biomolecules in various fields including medicine, veterinary science, environmental engineering, food engineering, agriculture, and
5 the like.

Further, with an external reference substance and a biochip according to the present invention, and a method for analyzing biomolecules using the same, it is possible to generate profiles of biomolecules contained in biosamples
10 including microorganisms, cells, and proteins using a significantly simple, cheap, and efficient method based on high throughput screening, and thus, the external reference substance, the biochip, and the method for analyzing biomolecules may be applied as useful tools for analyzing
15 biological significance of the biomolecules in various fields including medicine, veterinary science, environmental engineering, food engineering, agriculture, and the like.

In addition, with the external reference substance and the biochip according to the present invention, and the method for
20 analyzing biomolecules using the same, during the analysis of biological significance of the biomolecules, it is possible to detect biological functions of unknown biomolecules, to determine and identify structures thereof, and to select single-stranded nucleic acids specifically binding to the
25 biomolecules. Thus, the external reference substance and the

biochip according to the present invention, and the method for analyzing biomolecules may be used as tools for accurately understanding the functions of the biomolecules using the selected single-stranded nucleic acids.

5 Furthermore, with the external reference substance and the biochip according to the present invention, and the method for analyzing biomolecules using the same, biomolecules that can serve as diagnostic markers, can be used to monitor therapeutic results, can play important roles in the outbreak or the
10 progressions of diseases, are related to disease sensitivity, and can become target molecules for novel drug development, and the like, may be efficiently identified by a significantly cheap and simple method by analyzing the profile of the biomolecules medically associated with diseases.

15

Description of Drawings

FIG. 1 is a view showing a series of processes of determining a biomolecule-binding single-stranded nucleic acid and a quality control single-stranded nucleic acid using
20 biomolecules in a biosample composed of two or more biomolecules and a reference substance, determining an analysis single-stranded nucleic acid using a nucleic acid chip prepared based on base sequences of the single-stranded nucleic acids, and analyzing biological significance of the biomolecules in
25 the biosample using a nucleic acid chip prepared using the

analysis single-stranded nucleic acid and the quality control single-stranded nucleic acid,

FIG. 2 is a view showing a series of processes of preparing a nucleic acid chip using the biomolecule-binding
5 single-stranded nucleic acid and the quality control single-stranded nucleic acid to determine the analysis single-stranded nucleic acid,

FIG. 3 is a view showing a series of processes of preparing a nucleic acid chip for analyzing biological
10 significance of biomolecules in a biosample using the analysis single-stranded nucleic acid and the quality control single-stranded nucleic acid to generate a binding profile between the biomolecules in the biosample and the analysis single-stranded nucleic acid,

15 FIG. 4 is a view showing a series of processes of performing quality control using a reference substance I in a process of analyzing biological significance of biomolecules contained in a biosample using a nucleic acid chip prepared using an analysis single-stranded nucleic acid and a quality
20 control single-stranded nucleic acid,

FIG. 5 is a view showing a series of processes of performing quality control using a reference substance II in a process of analyzing biological significance of biomolecules contained in a biosample using a nucleic acid chip prepared
25 using an analysis single-stranded nucleic acid and a quality

control single-stranded nucleic acid,

FIG. 6 is a view showing a spot corresponding to a quality control single-stranded nucleic acid corresponding to a reference substance,

5 FIG. 7 is a view showing a process of diagnosing a disease using a program using a database of a human serum protein profile generated using a nucleic acid chip according to the present invention, and an artificial neural network algorithm,

10 FIG. 8 is a view showing a result of diagnosing a cardiovascular disease using a program using a database of a human serum protein profile generated using a reference substance and a nucleic acid chip according to the present invention, and the artificial neural network algorithm,

15 FIG. 9 is a view showing a result of diagnosing liver cancer using the program using a database of a human serum protein profile generated using the reference substance and the nucleic acid chip according to the present invention, and the artificial neural network algorithm,

20 FIG. 10 is a view showing a result of diagnosing metastasis of liver cancer using the program using the database of the human serum protein profile generated using the a reference substance and the nucleic acid chip according to the present invention, and the artificial neural network algorithm,

25 FIG. 11 is a view showing a sequence of a process of determining an amino acid sequence of a protein specifically

existing in a serum of a myocardial infarction patient in the database of the human serum protein profile generated using the reference substance and the nucleic acid chip according to the present invention,

5 FIG. 12 is a view showing the determined amino acid sequence of the protein specifically existing in the serum of the myocardial infarction patient in the database of the human serum protein profile generated using the reference substance and the nucleic acid chip according to the present invention,

10 FIG. 13 is a view showing a result obtained by binding a single-stranded nucleic acid secured by generating and analyzing a surface biomolecule profile of a small cell lung cancer (SCLC) cell line generated using the nucleic acid according to the present invention and the small cell lung
15 cancer cell line to each other,

FIG. 14 is a view showing specificity of a biomolecule-binding single-stranded nucleic acid secured by generating and analyzing surface biomolecule profiles of *E. coli* KCTC12006 and *Salmonella typhimurium* ATCC13311 using the nucleic acid chip
20 according to the present invention,

FIG. 15 is a view showing a result obtained by measuring degrees of contamination in foods contaminated with *E. coli*, using a biomolecule-binding single-stranded nucleic acid specifically binding to *E. coli*, selected using the nucleic
25 acid chip according to the present invention, and nano gold

particles,

FIG. 16 is a schematic view showing a process of generating biological significance using an external reference substance and a biochip according to the present invention, and

5 FIG. 17 is a schematic view showing a process of determining biomolecule-binding single-stranded nucleic acids associated with a method for preparing a biochip according to the present invention.

10 **Best Mode**

Reference will now be made in greater detail to an exemplary embodiment of the present invention, an example of which is illustrated in the accompanying drawings. Wherever possible, the same reference numerals will be used throughout
15 the drawings and the description to refer to the same or like parts.

The present invention provides a method for preparing an external reference substance and a biochip used to generate binding information on ligands and biomolecules; and a method
20 for analyzing biomolecules using the same, and the external reference substance and the biochip according to the present invention may be used to analyze biological significance of biomolecules contained in a biosample.

Definitions of terms used herein are as follows. That
25 is, the external reference substance, which is an external

molecule that is not contained in a biosample to be analyzed, may be used in quality control and quantitative analysis of the biochip.

A capture probe is a molecule having information on
5 ligands binding to biomolecules and the external reference substance, and is affixed onto the biochip.

A target probe, which is a molecule binding to the capture probe, is a mixture of an analysis target probe and a comparison target probe, or the target probe is composed of
10 the analysis target probe. The analysis target probe may be an analysis target probe derived from a ligand binding to a biomolecule in an analysis biosample, and the comparison target probe may be a comparison target probe derived from a ligand binding to a biomolecule in a comparison biosample or
15 artificially derived or artificially prepared from a pool of ligands binding to the biomolecule and external reference substance. Preferably, the target probe is composed of the analysis target probe and the comparison target probe.

A marker target probe, which is a molecule derived from a
20 ligand binding to a capture probe corresponding to a marker molecule and binding to the external reference substance, may be divided into an analysis marker target probe and a comparison marker target probe depending on purpose of use.

Binding information may mean a profile composed of spots
25 corresponding to capture probes configuring the biochip, or a

fluorescence intensity of each of the spots.

A method for preparing an external reference substance and a biochip according to the present invention includes: a first step of determining biomolecules that are not contained
5 in a biosample to be analyzed and preparing external reference substances using the determined external biomolecules; a second step of determining ligands binding to biomolecules and the external reference substances; a third step of determining a ligand for analyzing biological significance; and a fourth
10 step of synthesizing a capture probe using information on the determined ligand to affix the capture probe onto a substrate.

The method for preparing an external reference substance according to the present invention is as follows. In the case of examining a biosample using a biochip, for example,
15 transcripts, proteomes, or the like, may be examined. In the case of analyzing the transcripts, glyceraldehyde 3-phosphate dehydrogenase (GAPDH), actin mRNA, or the like, which is an internal marker, has been used for quality control, but there is no internal marker clearly used for quantitative analysis.
20 Further, in the case of analyzing the proteome, there is no useful internal marker. Therefore, in the case of analyzing the proteomes, there are many difficulties in quality control and quantitative analysis. Therefore, the present invention is intended to provide a quality control method and a
25 quantitative analysis method capable of being usefully used to

analyze a biosample using an external reference substance.

The external reference substance is a substance (or a molecule) that is not contained in the biosample to be analyzed, and in the case of analyzing a human-derived
5 biosample, for example, a plant-specific biomolecule may be used as a biomolecule that is not contained in the human-derived biosample. Currently, the human genome project and the Arabidopsis thaliana genome project (Arabidopsis thaliana is a kind of plant) were completed, and plant-specific
10 proteins were reported. According to the present invention, in the case of analyzing the human-derived biosample, the plant-specific protein may be used as the external reference substance.

Further, the ligands binding to the biomolecules
15 according to the present invention are as follows.

Examples of the ligands binding to the biomolecules and the external reference substance may include antibodies, peptides, single-stranded nucleic acids, aptamers, and the like.

20 In the case in which an aptamer (a single-stranded nucleic acid binding to a biomolecule in a three-dimensional structure) is used as a ligand binding to the biomolecules contained in a biosample, biomolecule-binding single-stranded nucleic acids may be determined using a reverse-SELEX method
25 (see Korean Patent No. 10-0923048) of reacting the biosample

containing the biomolecules with random single-stranded nucleic acids having random base sequences to determine the biomolecule-binding single-stranded nucleic acids binding to the biomolecules, and a ligand binding to the external
5 reference substance may be determined using a SELEX method. In the present invention, the aptamer is referred to as the analysis single-stranded nucleic acid, the biomolecule-binding single-stranded nucleic acid, or the like.

Further, a method for preparing a biochip for analyzing
10 biological significance according to the present invention may include affixing capture probes synthesized using at least one base sequence selected from base sequences of determined biomolecule-binding single-stranded nucleic acids and the external reference substance-binding single-stranded nucleic
15 acid and base sequences complementary thereto onto the substrate.

A method for determining a ligand having biological significance by using a biochip according to the present invention includes: preparing the biochip; reacting
20 biomolecule-binding single-stranded nucleic acids with biomolecules in a biosample to form biomolecule-single-stranded nucleic acid complexes, and separating the biomolecule-single-stranded nucleic acid complexes; separating single-stranded nucleic acids from the separated biomolecule-
25 single-stranded nucleic acid complexes, and amplifying and

labeling the separated single-stranded nucleic acids to
prepare analysis target probes; reacting mixed target probes
of the labeled analysis target probes and comparison target
probes with capture probes of the biochip to obtain binding
5 information through the labeling; and comparing the obtained
profile and pre-secured data on binding information to analyze
biological significance of the biomolecules.

FIG. 16 is a mimetic view showing a process of generating
biological significance using the external reference substance
10 and the biochip according to the present invention.

The basic principle of the external reference substance
and the biochip, and method for analyzing biomolecules using
the same, according to the present invention will be described
below. After affixing the capture probes including base
15 sequence information on single-stranded nucleic acids binding
to the biomolecules and the external reference substances onto
the biochip and reacting biomolecules to be tested with
single-stranded nucleic acids binding thereto to form
biomolecule-single-stranded nucleic acid complexes, a binding
20 profile of the capture probes of the biochip is obtained by
reacting a target probe with the capture probes, wherein in
the target probe, analysis target probes prepared from the
complexes and a comparison target probe are mixed with each
other, and characteristic of the binding profile are analyzed,
25 such that binding profile characteristics with respect to the

single-stranded nucleic acids binding to the biomolecules may be analyzed. Therefore, when the target probe having information on biomolecule-binding single-stranded nucleic acids is captured by complementary binding of the capture probes of the biochip, since the analysis target probes prepared through a process of amplifying the single-stranded nucleic acids separated from the biomolecule-single-stranded nucleic acid complexes are also produced in a state in which they include information identical or similar to profile information of the single-stranded nucleic acids of the complexes, at the time of analyzing the biomolecule, even though the target probes are analyzed using the capture probes of the biochip according to the present invention, the desired object may be achieved.

Further, in the obtaining of the binding information so as to recognize information on the biomolecules, the binding information may be generated by adding different amounts of external molecules configuring the external reference substances to the biosample to prepare the analysis target probe, or mixing different amounts of analysis marker target probes having information of ligands binding to the external molecules configuring the external reference substances with the analysis target probes to prepare the target probe. The comparison target probe may be prepared from a pool consisting of the ligands binding to biomolecules and ligands binding to

external reference substances.

In the case of analyzing biomolecules using the biochip according to the present invention, related data on binding information are accumulated, and a specific single-stranded
5 nucleic acid contributing to analysis of biological significance of the biomolecule may be naturally found therefrom, such that single-strand nucleic acids useful for analyzing biomolecules may be found.

The biosample to which the biochip according to the
10 present invention may be applied includes bacteria, fungi, viruses, cell lines, tissue, and the like, and biomolecules of which biological significance may be analyzed by the biochip according to the present invention includes one or more biomolecules selected from the group consisting of proteins,
15 carbohydrates, lipids, polysaccharides, glycoproteins, hormones, receptors, antigens, antibodies, enzymes, and nucleotides.

The first step of the method for preparing a biochip according to the present invention is a step of determining
20 target single-stranded nucleic acids binding to unknown biomolecules by reacting the biosample containing the biomolecules with single-stranded nucleic acids having random base sequences (hereinafter, referred to as 'random single-stranded nucleic acids').

25 Preferably, the determining of the single-stranded

nucleic acid binding to the biomolecules contained in the biosample includes: reacting the biomolecules of the biosample with the random single-stranded nucleic acids to prepare the biomolecule-single-stranded nucleic acid complexes, washing
5 the complexes, selecting biomolecule-single-stranded nucleic acid complexes having a binding affinity above a predetermined level on the basis of binding affinities between the single-stranded nucleic acids and the biomolecules, and separating and amplifying single-stranded nucleic acids from the selected
10 complexes; and inserting the amplified single-stranded nucleic acids into a cloning vector to secure a single clone and determining a base sequence thereof to determine biomolecule-binding single-stranded nucleic acids.

Selection and amplification of the biomolecule-single-
15 stranded complexes may be repeatedly performed several times, but since the biosample containing an unknown biomolecule is composed of a number of biomolecules and there are significant quantitative differences between the biomolecules, it is more preferable to prepare the biomolecule-binding single-stranded
20 nucleic acids using a linear method of performing selection and amplification once and intensify a washing process, rather than a cyclic method of repeatedly performing selection and amplification of the single-stranded nucleic acids binding to the biomolecules.

25 The random single-stranded nucleic acids having the

random base sequences may be prepared as random single-stranded RNAs through in vitro transcription after preparing double-stranded DNA using a single-stranded DNA oligonucleotide having the following random base sequence.

5 5'-GGGAGAGCGGAAGCGTGCTGGGCC N40 CATAACCCAGAGGTTCGATGG
ATCCCCCCC-3'

Here, underlined base sequences are invariable regions and N40 means the presence of bases such as adenine (A), guanine (G), thymine (T), cytosine (C), and the like, at equal
10 concentration at each position.

A forward (FW) primer (5'-GGGGGAATTCTAATACGA CTCACTATAGGGAGAGCGGAAGCGTGCTGGG-3') used in polymerase chain reaction (PCR) may form base-pairing with 5'-terminals of the underlined bases of the above base sequence, and include a
15 promoter base sequence for RNA polymerase of bacteriophage T7.

A reverse (RE) primer (5'-GGGGGGATCCATCGACCTCTGGGTTATG-3') used in PCR may form base pairing with 3'-terminals of the underlined bases of the above base sequence.

Preferably, in the method for preparing a biochip
20 according to the present invention, the biomolecule-binding single-stranded nucleic acids are single-stranded RNAs including 2'-F-substituted pyrimidine, and are synthesized by in vitro transcription and purified to thereby be prepared.

The synthesized random single-stranded nucleic acids may
25 be reacted with the biomolecules for 30 minutes by treating

the biosample with the synthesized random single-stranded nucleic acids, for example, at a concentration of 10^{15} base sequences/L.

In the cases of the target single-stranded nucleic acids, E. coli clone may be secured by inserting a product obtained by reverse-transcription (RT)-PCR into a cloning vector, and a base sequence thereof may be determined.

In this case, it is ideal that a reaction temperature is lower than a temperature for performing SELEX, and preferably, a reaction is performed at a temperature of 20°C to 37°C.

Generally, non-specific binding of the single-stranded nucleic acids binding to the biomolecules is prevented by treating excessive amounts of proteins and single-stranded nucleic acids, and preferably, yeast tRNA, salmon sperm DNA, or human placental DNA may be used.

In the second step of the method for preparing a biochip for determining biomolecule-binding single-stranded nucleic acid having biological significance, according to the present invention, capture probes are synthesized using at least one base sequence selected from base sequences of the single-stranded nucleic acids determined in the first step and the external reference substance-binding single-stranded nucleic acid, and the base sequences complementary thereto, and the synthesized capture probes are affixed onto the substrate, thereby preparing the biochip according to the present

invention.

Since the capture probe is a core factor having a large influence on a degree of hybridization, it is significantly important to determine base sequence configuration thereof.

5 Each of the capture probes affixed onto the biochip according to the present invention is composed of a characteristic base, and hybrids between capture single-stranded nucleic acids and target single-stranded nucleic acids need to maintain suitable T_m values. Therefore, a degree of hybridization of the

10 hybrids must be enough so that they can maintain their signals without contamination with fluorescent-labeled target probes.

Therefore, the base sequences of the capture probes may be determined based on the base sequences of the biomolecule-binding single-stranded nucleic acids selected from the random

15 single-stranded nucleic acids of the nucleic acid library in the first step and the base sequence of the external reference substance-binding single-stranded nucleic acid. In detail, the capture probe uses 40 nucleotides corresponding to a random portion of the nucleic acid library, or a part thereof,

20 and in the case of using the part, an artificial base sequence may be added. Preferably, the capture probes may be single-stranded nucleic acids of oligonucleotides having a base sequence of 10 bp to 20 bp.

In the case of analyzing a biosample using the biochip,

25 as the target probe, a double target probe or single target

probe is used. Generally, in the case of analyzing transcripts, a biosample derived from a disease site is set as an analysis biosample, a biosample derived from a normal site is set as a comparison biosample, an analysis target probe is prepared from the former, a comparison target probe is prepared from the latter, and then the analysis target probe and the comparison target probe are mixed with each other to thereby be used as a target probe. However, when there is no suitable comparison biosample, a single target probe derived from an analysis biosample is used as a target probe.

Further, the comparison target probe according to the present invention, which is a nucleic acid having a base sequence complementary to the capture probe, may be a single-stranded nucleic acid synthesized from a pool of ligands binding the biomolecules and ligands binding to the external reference substance. Preferably, the comparison target probe may be single-stranded nucleic acids of oligonucleotides having a base sequence of 80 bp to 140 bp.

The marker target probe is derived from a ligand binding to an external molecule configuring the external reference substance, and may be divided into an analysis marker target probe and a comparison marker target probe. In the case of preparing the analysis marker target probe by mixing the external reference substances with the biosample, the analysis marker target probe may be prepared together with the analysis

target probe in a process of preparing the analysis target probe. Alternatively, in the case of using the external reference substances without mixing with the biosample, the analysis marker target probe capable of binding to the capture probe of the external reference substance may be prepared, and a mixture of the analysis marker target probe and the analysis target probe may be used. The comparison market target probe may be prepared from a pool of the ligands binding to the biomolecules and ligands binding to the external reference substance.

As the target probe according to the present invention, preferably, a mixture of the analysis target probe including the marker target probe and the comparison target probe including the marker target probe may be used.

Further, in the method for preparing a biochip according to the present invention, as the substrate, a substrate made of an inorganic material such as glass, silicon, or the like, or a polymer material such as acrylic polymers, polyethylene terephthalate (PET), polycarbonate, polystyrene, polypropylene, or the like, may be used. Preferably, the substrate may be a slide glass made of glass. In this case, a substrate coated with an amine group, an aldehyde group, or the like, may be used. For example, the biochip is prepared by arranging and affixing capture probes in a constant order using an UltraGAPSTM Coated Slide (Corning Inc.), which is a

gamma amino propyl silane (GAPS)-coated glass slide.

In the method for preparing a biochip according to the present invention, a microarrayer system may be used, and each of the capture probes is dissolved in buffer to adjust a concentration. At this time, a humidity of 70%-80% is maintained inside the arrayer system while spotting is performed. After being kept in a humidified chamber, the spotted slides are baked in a UV crosslinker.

As described above, the biochip according to the present invention is stored in a state in which, after fixing the capture probes to the glass slide using a method widely known in the art and directly drying the slide by centrifugation, light is blocked before the biochip is used.

A biochip on which the capture probes are regularly arranged may be prepared using various methods known in the art (M. schena; DNA microarray; a practical approach, Oxford, 1999).

As long as the biochip according to the present invention may analyze biological significance of an unknown biomolecule with equal or similar accuracy, in view of manufacturing cost of the biochip and analysis efficiency, it is preferable to reduce the number of capture probes affixed onto the biochip.

For this reason, the method for preparing a biochip according to the present invention may further include reducing the number of capture probes to be affixed onto the

biochip according to the present invention by analyzing a degree of contribution of each of the capture probes to analyzing biological significance of an unknown biomolecule and selecting the capture probes on the basis of the analyzed
5 degree of contribution in a range in which the biological significance of the biomolecule may be analyzed.

Further, the present invention provides a reference substance and a nucleic acid chip for generating binding information on biomolecules in a biosample composed of two or
10 more biomolecules and analysis single-stranded nucleic acids while performing internal quality control, a method for preparing the same, and a method and an apparatus for analyzing biomolecules using the same. The reference substance and the nucleic acid chip according to the present
15 invention are used to analyze biological significance of the biomolecules contained in the biosample.

The nucleic acid chip indicates a supporter onto which a nucleic acid ligand is affixed in order to simultaneously analyzing one or more substances. Preferably, the supporter
20 may be a solid glass or nylon substrate. The nucleic acid chip is produced in a form of a two-dimensional probe matrix manufactured on the solid glass or nylon substrate. It is significantly preferable to perform analysis for as many as possible characteristics in a single nucleic acid chip.
25 Therefore, there is a need to significantly increase a density

and an amount of the probe in the single substrate. In general, a microarray having probe fixation sites smaller than 500nm (that is, having a density larger than 400 probes/cm²) is referred to as a high-density microarray, and the other
5 microarrays are referred to as "low-density" microarrays. In general, the nucleic acid chip is used to get information on a nucleic acid in an unknown sample through hybridization of an unknown nucleic acid sample with an already known nucleic acid fixed by arranging nucleic acids having various base sequences
10 (hundreds to hundreds of thousands) in a small space. A nucleic acid microarray has an advantage in that it may simultaneously detect at least hundreds or more base sequence sites within a short time while replacing an existing southern blot method, northern blot method, mutation analysis method,
15 or the like.

In general, a reference substance is an internal quality control substance for comparison at the time of qualitative and quantitative analysis, various tests, examinations, and in the present invention, the reference substance means a
20 substance for internal quality control at the time of qualitative and quantitative analysis in analyzing the biomolecules in the biosample composed of two or more biomolecules to be analyzed using the analysis single-stranded nucleic acid. It is ideal that the reference substance is a
25 substance constantly present in a sample to be analyzed at a

predetermined amount. Otherwise, an external substance, a substance that is not contained in the sample, may be used. Preferably, in the case in which the sample to be analyzed is a biosample, the reference substance may be composed of
5 external biomolecules that are not contained in the biosample. Quality control means internal quality control of analyzing a group of test results obtained at every time measurement to control precision of measured values without using external standard such as a control sample.

10 In the present invention, a single-stranded nucleic acid that has a base sequence of a single-stranded nucleic acid secured and determined by reacting biomolecules in a biosample composed of two or more biomolecules with a nucleic acid library composed of random single-stranded nucleic acids
15 having random base sequences, and of which a stable secondary structure will be predicted is referred to as a binding single-stranded nucleic acid, and a single-stranded nucleic acid selected using the profile secured in order to analyze biological significance using a nucleic acid chip prepared
20 based on the binding single-stranded nucleic acid is referred to as an analysis single-stranded nucleic acid. Further, a single-stranded nucleic acid determined for quality control as a single-stranded nucleic acid binding to the reference substance is referred to as a quality control single-stranded
25 nucleic acid. All of these single-stranded nucleic acids are

aptamers.

In the present invention, the term "aptamer" means a small (20 to 60 nucleotides) single-stranded nucleic acid (DNA or RNA) fragment capable of binding to various kinds of
5 receptors from a low molecular compound to proteins with high affinity and specificity. Development of the aptamer is performed in a test tube by SELEX. SELEX, which is the abbreviation for 'systematic evolution of ligands by
exponential enrichment', was initially developed in 1990
10 (Tuerk, C. and Gold, L., 1990, Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249 (4968), 505-510; Ellington, A.D. and Szostak, J.W., 1990, In vitro selection of RNA molecules that bind specific ligands. Nature 346 (6287), 818-822). A nucleic
15 acid aptamer having a high binding affinity to a specific molecule may be obtained using SELEX. The aptamer is considered as a nucleic acid molecule having characteristics similar to those of an antibody in that it has a high binding affinity and selectivity to a receptor at a level of nano
20 moles to pico moles. The aptamer is selected in a test tube through SELEX. The central principle of SELEX is significantly similar to a concept of evolution that among a large number of randomly existing individuals, only individuals having a specific characteristic can survive, and
25 the individuals that survived as described above gradually

account for a large portion in the group, thereby dominating the group. However, an individual in SELEX is a single-stranded nucleic acid, and a selective pressure is a binding affinity to a specific receptor. Therefore, there is a need to form a nucleic acid library having a large number of random sequences, a fraction process capable of selecting individuals having a high binding affinity to a specific receptor expected to be present in this library is required, and an amplification step of amplifying the selected aptamer to increase a ratio thereof in the pool of nucleic acids so as to perform selection in next round is required. A specific method, reagents/materials, and the like, for aptamers in SELEX were known in the art (Marshall, K.A. and Ellington, A.D., 2000, In vitro selection of RNA aptamers. Methods Enzymol 318, 193-214; Fitzwater, T. and Polisky, B., 1996, A SELEX primer. Methods Enzymol 267, 275-301). Further, the present inventor suggested a method for selecting a single-stranded nucleic acid specifically binding to each biomolecule by reacting the biomolecules in a biosample composed of two or more biomolecules with a nucleic acid library composed of random single-stranded nucleic acids having random base sequences (Korean Patent No. 10-0923048).

The present invention provides a method for analyzing a biomolecule by an analysis single-stranded nucleic acid, wherein a quality control reference substance for analyzing an

analysis single-stranded nucleic acid binding to biomolecules in a biosample composed of two or more biomolecules is used, and the binding single-stranded nucleic acid is selected from a nucleic acid library composed of random single-stranded nucleic acids having random base sequences, whereby internal quality control is performed by analyzing a quality control single-stranded nucleic acid using a nucleic acid analysis method.

Further, the present inventor suggested a method of analyzing an aptamer in a biomolecule-aptamer complex produced by reacting a biomolecule in a biosample with the aptamer using a nucleic acid analysis method to analyze the biomolecule, which is a receptor (Korean Patent No. 10-0670799). The nucleic acid analysis method for analyzing the aptamer in the biomolecule-aptamer complex in the biosample may be performed using polymerase chain reaction (PCR), ligase chain reaction (LCR), strand displacement amplification (SDA), transcription-mediated amplification (TMA), branched DNA, invader assay, rolling circle amplification (RCA), and the like. Preferably, an amplification product produced by PCR using a single-stranded nucleic acid in the biomolecule-single-stranded nucleic acid complex as a template may be additionally analyzed.

Further, the present invention provides the method for selecting a biomolecule analysis single-stranded nucleic acid, wherein the quality control reference substance is a

biomolecule that is not contained in the biosample.

FIG. 1 shows a series of processes of reacting the biomolecule in the biosample and the reference substance with random single-stranded nucleic acids having random base sequences to determine the binding single-stranded nucleic acid and the quality control single-stranded nucleic acid, and analyzing biological significance of the biomolecule in the biosample using a nucleic acid chip prepared using base sequences of the analysis single-stranded nucleic acid and the quality control single-stranded nucleic acid.

Representative examples of the biosample tested using the nucleic acid chip may include transcripts, proteome, and the like. In the case of analyzing a dead body, glyceraldehyde 3-phosphate dehydrogenase (GAPDH), β -actin mRNA, or the like, which is expressed in a constant amount in almost every tissue, has been used for internal quality control as a reference substance, but there is no reference substance for accurate quantitative analysis. Therefore, accuracy of quantitative analysis is dependent on external quality control.

In addition, as a method for selecting a ligand binding to proteins in a biosample composed of two or more proteins, there are reverse-SELEX suggested by the present inventor (Korean Patent No. 10-0923048) and cell-SELEX (Homann, M. and Goring, H.U., 1999, Nucleic Acids Res. 27 (9), 2006-2014).

The present invention is intended to provide a quality control reference substance for efficiently selecting a ligand binding to a biomolecule in a biosample containing two or more biomolecules using reverse-SELEX.

5 Further, in the case of analyzing proteome, since there is no useful reference substance capable of being used in qualitative and quantitative analysis, there are a lot of difficulties in quality control and quantitative analysis for analyzing the proteome. Therefore, the present invention is
10 intended to provide a useful internal quality control and quantitative analysis method for analyzing a sample using a reference substance.

Preferably, in the case of analyzing a human-derived biosample, as the reference substance according to the present
15 invention, a plant-specific biomolecule, which is a biomolecule that is not contained in the human-derived biosample, may be used, similarly to the external reference substance as described above. Currently, the human genome project and the Arabidopsis thaliana genome project
20 (Arabidopsis thaliana is a kind of plant) were completed, and plant-specific proteins were reported. In the present invention, as a reference substance for analyzing a human-derived biosample, the plant-specific protein may be used.

Substances binding to the biomolecules contained in the
25 biosample and the reference substances may include antibodies,

peptides, single-stranded nucleic acids, and the like, and preferably, the substances may be the single-stranded nucleic acids.

The present invention provides a method for selecting a biomolecule analysis single-stranded nucleic acid so as to generate binding profiles between biomolecules and binding single-stranded nucleic acids using a biosample, a reference substance, a binding single-stranded nucleic acid, a quality control single-stranded nucleic acid, and a nucleic acid chip, in order to select an analysis single-stranded nucleic acid for analyzing biological significance of biomolecules, the method including: determining a biomolecule that is not contained in the biosample and preparing the quality control single-stranded nucleic acid from the determined external biomolecules; preparing the binding single-stranded nucleic acids from the biomolecules contained in the biosample; and preparing a supporter onto which capture probes synthesized using base sequences of the quality control single-stranded nucleic acid and the binding single-stranded nucleic acid are affixed.

FIG. 2 shows a series of processes of selecting the binding single-stranded nucleic acid of the biomolecule in the biosample and the quality control single-stranded nucleic acid to prepare a nucleic acid chip, and analyzing biological significance of the biomolecules in the biosample.

A method for determining the quality control single-stranded nucleic acid among single-stranded nucleic acids binding to the reference substances according to the present invention may be performed by a standard SELEX method (Tuerk
5 C. and Gold L., 1990, Science, 249; 505-510) of reacting the reference substance and random single-stranded nucleic acids having random base sequences to separate the reference substances and the single-stranded nucleic acid and repeatedly performing this series of selection and amplification to
10 select the single-stranded nucleic acid binding to the reference substance.

Further, in a method for selecting a single-stranded nucleic acid binding to the biomolecule present in a biosample composed of two or more biomolecules according to the present
15 invention, a reverse-SELEX method (Korean Patent No. 10-0923048) of reacting the biosample containing the biomolecules with random single-stranded nucleic acids having random base sequences to determine biomolecule-binding single-stranded nucleic acids binding to the biomolecules may be used.

20 A method for preparing the binding single-stranded nucleic acids provided in the present invention, which is the same as the method for selecting a single-stranded nucleic acid binding to the biomolecule contained in the biosample as described above, may include: selecting biomolecule-single-
25 stranded nucleic acid complexes in a reaction solution

obtained by reacting the biomolecules with random single-stranded nucleic acids having random base sequences; separating the single-stranded nucleic acids from the complexes and amplifying the separated single-stranded nucleic acids to prepare single-stranded DNAs, and inserting the single-stranded DNAs into a cloning vector to secure a single clone and preparing the binding single-stranded nucleic acids through base sequencing of the single-stranded nucleic acid, thereby making it possible to select the biomolecule analysis single-stranded nucleic acid.

The present invention provides a method for selecting a biomolecule analysis single-stranded nucleic acid, wherein in the selecting of the biomolecule-single-stranded nucleic acid complexes, the biomolecule-single-stranded nucleic acid complexes in the reaction solution are washed and biomolecule-single-stranded nucleic acid complexes having a binding affinity above a predetermined level on the basis of binding affinities between the single-stranded nucleic acids and the biomolecules are selected.

The present invention provides the method for selecting a biomolecule analysis single-stranded nucleic acid, wherein in the selecting of the biomolecule-single-stranded nucleic acid complexes, the biomolecule-single-stranded nucleic acid complexes are selected by performing capillary electrophoresis on the reaction solution.

The present invention provides the method for selecting a biomolecule analysis single-stranded nucleic acid, wherein in the selecting of the biomolecule-single-stranded nucleic acid complexes, the biomolecule-single-stranded nucleic acid
5 complexes are selected by treating the reaction solution with a structure of nitrocellulose and nylon.

The present invention provides the method for selecting a biomolecule analysis single-stranded nucleic acid, wherein selection and amplification of the biomolecule-single-stranded
10 nucleic acid complexes are repeatedly performed several times.

In the present invention, the biomolecule-single-stranded nucleic acid complexes may be selected by the method of washing the formed biomolecule-single-stranded nucleic acid complexes and selecting biomolecule-single-stranded nucleic
15 acid complexes having a binding affinity above a predetermined level on the basis of binding affinities between the single-stranded nucleic acids and the biomolecules, the method of performing electrophoresis on the reaction solution to select the biomolecule-single-stranded nucleic acid complexes, the
20 method of treating the reaction solution with the structure of nitrocellulose and nylon to select the biomolecule-single-stranded nucleic acid complexes, and the like.

Products obtained by performing reverse transcription (RT)-PCR on the single-stranded nucleic acids separated from
25 the biomolecule-single-stranded nucleic acid complexes are

inserted into cloning vectors to secure E. coli clones, and base sequences of the single-stranded nucleic acids may be determined.

The present invention provides the method for selecting a
5 biomolecule analysis single-stranded nucleic acid, wherein the supporter onto which the capture probe is affixed is selected from a glass slide, a sensing surface of a biosensor, beads, nanoparticles, and the like.

The present invention provides the method for selecting a
10 biomolecule analysis single-stranded nucleic acid, wherein the capture probe is composed of and synthesized from at least one base sequence selected from base sequences of the binding single-stranded nucleic acids and the quality control single-stranded nucleic acid and base sequences complementary
15 thereto.

The present invention provides the method for selecting a biomolecule analysis single-stranded nucleic acid, wherein the generating of the binding profiles between the biomolecules in the biosample composed of two or more biomolecules and binding
20 single-stranded nucleic acids includes: preparing analysis target probes containing a labeling substance from the reference substance, the biosample, the quality control single-stranded nucleic acid, and the binding single-stranded nucleic acids; preparing comparison target probes containing a
25 labeling substance by mixing and amplifying the binding

single-stranded nucleic acids corresponding to the capture probes and the quality control single-stranded nucleic acid; preparing target probes by mixing the analysis target probes and the comparison target probes with each other; and
5 generating the binding profiles by performing a hybridization reaction between the target probes and the capture probes on the supporter.

The present invention provides the method for selecting a biomolecule analysis single-stranded nucleic acid, wherein the
10 preparing of the analysis target probes includes: preparing an analysis sample obtained by adding a reference substance I composed of different amounts of reference substances to the biosample; separating biomolecule-single-stranded nucleic acid complexes and reference substance-single-stranded nucleic acid
15 complexes formed by reacting the analysis sample with the single-stranded nucleic acids composed of the binding single-stranded nucleic acids and the quality control single-stranded nucleic acid; and preparing the analysis target probes by separating the single-stranded nucleic acids from the
20 separated complexes and amplifying and labeling the separated single-stranded nucleic acids.

The present invention provides the method for selecting a biomolecule analysis single-stranded nucleic acid, wherein the preparing of the analysis target probe includes: separating
25 single-stranded nucleic acids from the biomolecule-single-

stranded nucleic acid complexes formed by reacting the biosample with the binding single-stranded nucleic acids; and preparing the analysis target probes by mixing a reference substance II composed of different amounts of quality control
5 single-stranded nucleic acids with the separated single-stranded nucleic acids and performing amplification and labeling thereon.

The present invention provides a method for selecting a biomolecule analysis single-stranded nucleic acid, in order to
10 analyze biological significance of the biomolecules, wherein the method further includes reducing the number of capture probes to be affixed onto the biochip by selecting the capture probes on the basis of the degree of contribution of the capture probes in a range in which the biological significance
15 of the biomolecule may be analyzed.

The present invention provides a nucleic acid chip, wherein capture probes synthesized using base sequences of the binding single-stranded nucleic acids and quality control single-stranded nucleic acid are affixed onto a supporter of
20 the nucleic acid, and the nucleic acid chip is used to generate binding information on the binding single-stranded nucleic acids and the quality control single-stranded nucleic acid for selecting the analysis single-stranded nucleic acid.

In a method for selecting an analysis single-stranded
25 nucleic acid using the nucleic acid chip according to the

present invention, the capture probes, which are molecules affixed onto the supporter, may be single-stranded nucleic acids binding to the biomolecules and the reference substance, or may be composed of one or more substances selected from
5 substances having information on the single-stranded nucleic acids.

The binding information on the biomolecules in the biosample and the single-stranded nucleic acids indicates signals generated by complementary binding between the target
10 probes prepared from the binding single-stranded nucleic acids and the capture probes. Preferably, the binding information means profiles composed of spots corresponding to the capture probes configuring the supporter, and preferably, fluorescence intensities as signals generated from the labeling substance
15 in the binding single-stranded nucleic acid in the target probe binding to each of the capture probes configuring respective spots. The binding information is a combination of signals of the analysis target probe and the comparison target probe of the target probe. Ultimately, the binding
20 information indicates a distribution state of the biomolecule-binding single-stranded nucleic acids in the biosample, and a distribution state of the biomolecules binding to the single-stranded nucleic acids may be deduced therefrom.

Further, in a nucleic acid chip for selecting an analysis
25 single-stranded nucleic acid in order to analyze biological

significance of biomolecules in the biosample according to the present invention, capture probes synthesized using at least one base sequence selected from the base sequences of the determined analysis single-stranded nucleic acid and the quality control single-stranded nucleic acid and base sequences complementary thereto, or synthesized using capture probes having base sequences forming a completely complementary binding with the base sequences of the biomolecule-binding single-stranded nucleic acids are affixed
10 onto the supporter.

In addition, according to the present invention, the supporter onto which the capture probes may be affixed may be selected from a glass slide, a sensing surface of a bio sensor, beads, nanoparticles, and the like, and preferably,
15 the supporter may be the glass slide.

A method for amplifying signals of amplification products binding to the capture probes may be selected depending on the kind of supporter.

As described above, the biochip according to the present invention is stored in a state in which, after affixing the capture probes onto the glass slide and directly drying the slide by centrifugation, light is blocked before the biochip is used.
20

A nucleic acid chip on which the capture probes are regularly arranged may be prepared using various methods known
25

in the art (M. schena; DNA microarray; a practical approach, Oxford, 1999).

When a biosample is analyzed using a nucleic acid chip, generally, in the case of analyzing transcripts, a biosample
5 derived from a disease site is set as an analysis biosample, a biosample derived from a normal site is set as a comparison biosample, an analysis target probe is prepared from the former, a comparison target probe is prepared from the latter, and then the analysis target probe and the comparison target
10 probe are mixed with each other to thereby be used as a target probe. However, when there is no suitable comparison biosample, a single target probe derived from an analysis biosample may also be used as a target probe.

Preferably, the target probe may be single-stranded
15 nucleic acids of oligonucleotides having a base sequence of 80 bp to 140 bp.

Further, in the present invention, the analysis target probe may be prepared using the following two methods: in one method, the analysis target probe may be prepared by mixing
20 the reference substance I composed of different amounts of reference substances with the biosample, and in the other method, the analysis target probe may be prepared by mixing the reference substance II composed of different amounts of quality control single-stranded nucleic acids with the single-
25 stranded nucleic acids separated from the biomolecule-single-

stranded nucleic acid complexes.

The comparison target probe, which is a nucleic acid having a base sequence complementary to the capture probe, may be a single-stranded nucleic acid synthesized from a pool of
5 single-stranded nucleic acids composed of the biomolecule-binding single-stranded nucleic acids and the quality control single-stranded nucleic acids.

For this reason, the analysis single-stranded nucleic acids useful for analyzing biomolecules may be found by
10 analyzing a degree of contribution of each of the capture probes to analyzing biological significance of the biomolecules and selecting capture probes on the basis of the analyzed degree of contribution in a range in which the biological significance of the biomolecules may be analyzed.

15 The present invention provides a method for analyzing biomolecules, wherein the quality control reference substance for analyzing biomolecules in the biosample using the analysis single-stranded nucleic acid is used, and internal quality control is performed by analyzing the quality control single-
20 stranded nucleic acid using a nucleic acid analysis method.

Further, the present invention provides a method for analyzing biomolecules, wherein analysis of the biomolecules in the biosample using the analysis single-stranded nucleic acid is performed by the nucleic acid analysis method.

25 FIG. 3 shows a series of processes of preparing the

nucleic acid chip for analyzing biological significance of biomolecules in a biosample using the analysis single-stranded nucleic acid and the quality control single-stranded nucleic acid to generate a binding profile between the biomolecules in the biosample and the analysis single-stranded nucleic acid.

The present inventor suggested a method for analyzing an aptamer in a biomolecule-aptamer complex produced by reacting a biomolecule in a biosample with the aptamer using a nucleic acid analysis method to analyze the biomolecule, which is a receptor (Korean Patent No. 10-0670799-0000). The nucleic acid analysis method for analyzing biomolecules in the biosample and the aptamer in the biomolecule-aptamer complex may be performed using polymerase chain reaction (PCR), ligase chain reaction (LCR), strand displacement amplification (SDA), transcription-mediated amplification (TMA), branched DNA, invader assay, rolling circle amplification (RCA), and the like. Preferably, an amplification product produced by PCR using a nucleic acid in the biomolecule-single-stranded nucleic acid complex as a template may be additionally analyzed.

Further, the present invention provides the method for analyzing biomolecules, wherein the quality control reference substance is a biomolecule that is not contained in the biosample.

The present invention provides the method for analyzing

biomolecules, the method including: affixing the capture probes synthesized using base sequences of the analysis single-stranded nucleic acid and the quality control single-stranded nucleic acid onto a supporter; preparing a target probe containing a labeling substance from the reference substance, the biosample, the quality control single-stranded nucleic acid, and the analysis single-stranded nucleic acid; obtaining binding information by performing a hybridization reaction between the target probe and the capture probe on the supporter; and comparing the obtained binding information and pre-secured data on binding information to analyze biological significance of the biomolecules.

In addition, the present invention provides the method for analyzing biomolecules, wherein the preparing of the target probe includes: preparing an analysis target probe containing the labeling substance from the reference substance, the biosample, the quality control single-stranded nucleic acid, and the analysis single-stranded nucleic acid; preparing a comparison target probe containing the labeling substance by mixing and amplifying the analysis single-stranded nucleic acid corresponding to the capture probe and the quality control single-stranded nucleic acid; and preparing a target probe composed of the analysis target probe and the comparison target probe.

FIGS. 4 and 5 show a series of processes of performing

analysis using the reference substance and the quality control single-stranded nucleic acid for quality control, in a process of preparing a nucleic acid chip using the analysis single-stranded nucleic acid and the quality control single-stranded
5 nucleic acid to analyze biological significance of the biomolecules contained in the biosample.

The present invention provides the method for analyzing biomolecules, wherein the supporter onto which the capture probes are affixed may be selected from a glass slide, a
10 sensing surface of a biosensor, beads, nanoparticles, and the like.

The present invention provides the method for analyzing biomolecules, wherein the capture probe is composed of base sequences forming completely complementary binding with base
15 sequences of the analysis single-stranded nucleic acid and the quality control single-stranded nucleic acid.

Preferably, the capture probe may be composed of a base sequence forming complementary binding with the analysis single-stranded nucleic acid, wherein the analysis single-stranded nucleic acid is an aptamer selected from the binding
20 single-stranded nucleic acids configuring the biosample and used for analyzing biological significance of the biomolecules in the biosample. Therefore, since the capture probe may form complementary binding with a base sequence of a specific
25 analysis single-stranded nucleic acid in an amplification

product obtained by performing PCR using the analysis single-stranded nucleic acid in the complex as a template, ultimately, a protein corresponding to a receptor may be quantitatively analyzed using a result obtained by analyzing
5 the analysis single-stranded nucleic acid in the complex.

A method for amplifying signals of amplification products binding to the capture probes may be selected depending on the kind of supporter.

In a method for analyzing biological significance of
10 biomolecules using the nucleic acid chip while performing internal quality control according to the present invention, capture probes, which are molecules affixed onto a supporter, may be single-stranded nucleic acids binding to the biomolecules and a reference substance or be composed of one
15 or more substances selected from substances having information on the single-stranded nucleic acids.

The present invention provides the method for analyzing biomolecules, wherein a primer containing a labeling substance, for labeling and amplifying single-stranded nucleic
20 acids separated from the biomolecule-single-stranded nucleic acid complex and the reference substance-single-stranded nucleic acid complex is used.

Further, in the present invention, a primer containing a labeling substance, for labeling and amplifying single-
25 stranded nucleic acids separated from the biomolecule-single-

stranded nucleic acid complex and the reference substance-
single-stranded nucleic acid complex, and primer having a tag
directing a specific single-stranded nucleic acid may be used.

The term "tag" means unique nucleotide sequences used to
5 identify polynucleotides and/or track the origin of the
polynucleotides in a reaction. A tag sequence may be present
at the 5-terminal or 3-terminal of the primer. The base
sequences of the capture probes may be variously changed in
size and compositions; the following references provide
10 guidance for selecting sets of capture probes appropriate for
particular embodiments (U.S. Patent No. 5,635,400; Brenner et
al, 2000, PNAS., 97: 1665-1670; Shoemaker et al, 1996, Nature
Genetics, 14: 450-456; EP Patent Publication No. 0799897A1;
U.S. Patent No. 5,981,179, and the like). In particular
15 embodiments, the base sequence of the capture probe may have a
length in a range of 4 to 36 nucleotides, 6 to 30 nucleotides,
or 8 to 20 nucleotides.

The present invention provides the method for analyzing
biomolecules, wherein the capture probe is composed of base
20 sequences forming completely complementary binding with a base
sequence of the tag directing the analysis single-stranded
nucleic acid and the quality control single-stranded nucleic
acid.

The capture probe may be prepared using a base sequence
25 complementary to the tag, and since this capture probe may

form completely complementary binding with the base sequence of the tag in a PCR product formed by performing PCR using an analysis single-stranded nucleic acid in the complex as a template, the PCR product may be analyzed, and the analysis
5 single-stranded nucleic acid in the complex may be analyzed by analyzing signals of spots generated by the capture probe and the PCR product.

The comparison target probe, which is a nucleic acid having a base sequence complementary to the capture probe, may
10 be a single-stranded nucleic acid synthesized from a pool of single-stranded nucleic acids composed of the biomolecule-binding single-stranded nucleic acids and the quality control single-stranded nucleic acids.

Generally, in the case of analyzing transcripts using a
15 nucleic acid chip, a biosample derived from a disease site is set as an analysis biosample (experimental biosample), a biosample derived from a normal site is set as a comparison biosample (control biosample), an analysis target probe is prepared from the former, a comparison target probe is
20 prepared from the latter, and then the analysis target probe and the comparison target probe are mixed with each other to thereby be used as a target probe. However, when there is no suitable comparison biosample, a single target probe derived from the analysis biosample may also be used as the target
25 probe.

Further, in the present invention, the analysis target probe may be prepared using following two methods: In one method, the analysis target probe may be prepared by mixing the reference substance I composed of different amounts of reference substances with the biosample, and in the other method, the analysis target probe may be prepared by mixing the reference substance II composed of different amounts of quality control single-stranded nucleic acids with the single-stranded nucleic acids separated from the biomolecule-single-stranded nucleic acid complexes.

The present invention provides the method for analyzing biomolecules, wherein the preparing of the analysis target probe includes: preparing an analysis sample obtained by adding a reference substance I composed of different amounts of reference substances to the biosample; separating biomolecule-single-stranded nucleic acid complexes and reference substance-single-stranded nucleic acid complexes formed by reacting the analysis sample with single-stranded nucleic acids composed of the analysis single-stranded nucleic acids and the quality control single-stranded nucleic acid; and preparing the analysis target probe by separating the analysis single-stranded nucleic acids from the complexes and amplifying and labeling the separated analysis single-stranded nucleic acids.

The present invention provides a method for analyzing

biomolecules, wherein the preparing of the analysis target probe includes: separating biomolecule-single-stranded nucleic acid complexes formed by reacting the biomolecules in the biosample with the analysis single-stranded nucleic acids; and
5 mixing the reference substance II composed of different amounts of quality control single-stranded nucleic acids with the analysis single-stranded nucleic acid separated from the separated biomolecule-single-stranded nucleic acid complex and amplifying and labeling the mixture to prepare the labeled
10 analysis target probe.

The present invention provides a method and an apparatus for analyzing biomolecules, wherein a nucleic acid chip is analyzed using a target probe prepared by mixing an analysis target probe and a comparison target probe with each other,
15 the analysis target probe being prepared by reacting an analysis single-stranded nucleic acid with biomolecules in a biosample (experimental biosample) and a comparison target probe being prepared by reacting the analysis single-stranded nucleic acid with biomolecules in a biosample (control
20 biosample).

A target probe derived from an analysis single-stranded nucleic acid binding to the biomolecule in the experimental biosample is referred to as the analysis target probe, and a target probe derived from an analysis single-stranded nucleic
25 acid binding to the biomolecule in the control biosample or

artificially prepared from a pool of analysis single-stranded nucleic acids binding to biomolecules and reference substances is referred to as the comparison target probe. Preferably, the target probe is composed of the analysis target probe and
 5 the comparison target probe.

The target probe, which is a molecule binding to the capture probe, may be composed of a mixture of the analysis target probe and the comparison target probe, or be composed of only the analysis target probe.

10 The present invention provides a method and an apparatus for analyzing biomolecules, wherein as the labeling substance, a fluorescent pigment selected from biotin, Cy2, GFP, YO-PRO-1, YOYO-1, Calcein, FITC, FlourX, ALEXA 488, Rhodamine 110, ABI 5-FAM, Oregon Green 500, Oregon green 488, RiboGreen,
 15 Rhodamine Green, Rhodamine 123, Magnesium Green, Calcium Green, TO-PRO-1, TOTO-1, ABI JOE, BODIPY 530/550, Dil, BODIPY TMR, BODIPY558/568, BODIPY564/570, Alexa 546, TRITC, Magnesium Orange, Phycoerythrin R & B, Rhodamine Phalloidin, Calcium Orange, Pyronin Y, Rhodamine B, ABI TAMRA, Rhodamine Red,
 20 Cy3.5, ABI ROX, Calcium Crimson, Alexa 594, Texas Red, Nile Red, YO-PRO-3, YOYO-3, R-phycocyanin, C-phycocyanin, TOPRO-3, TOTO-3, DiD DilC(5), Thiadicarbocyanine, Cy5.5, Cy5, and Cy3 is used.

When an amplification product secured by performing PCR
 25 using the analysis single-stranded nucleic acid in the complex

formed by reacting the analysis single-stranded nucleic acid with the biomolecule in the biosample as a template and the primer containing the labeling substance is reacted with the capture probe, the capture probe forms complementary binding
5 with the single-stranded nucleic acid of the amplification product containing the labeling substance, thereby forming a double-stranded nucleic acids. Therefore, in spots composed of the capture probes, when a signal based on the labeling substance is generated, the analysis single-stranded nucleic
10 acid may be analyzed through the signal, and the protein, which is the receptor in the complex formed by the analysis single-stranded nucleic acid, may be quantitatively analyzed. Therefore, the labeling substance may be selected within various ranges depending on analysis purpose, and preferably,
15 Cy3 or Cy5 may be used.

The present invention provides a nucleic acid chip, wherein the capture probes prepared using base sequences of the analysis single-stranded nucleic acids and the quality control single-stranded nucleic acids are affixed onto a
20 supporter of the nucleic acid chip, and the nucleic acid chip is used to form binding information on the biomolecules and the analysis single-stranded nucleic acids for analyzing biological significance of the biomolecules in the biosample.

Further, in a nucleic acid chip for analyzing biological
25 significance of biomolecules in a biosample according to the

present invention, capture probes synthesized using at least one base sequence selected from base sequences of the determined analysis single-stranded nucleic acid and the quality control single-stranded nucleic acid and base
5 sequences complementary thereto, or synthesized using capture probes having base sequences forming completely complementary binding with tags directing base sequences of the biomolecule-binding single-stranded nucleic acid and the quality control single-stranded nucleic acid are affixed onto the supporter.

10 A nucleic acid chip on which the capture probes are regularly arranged may be prepared using various methods known in the art (M. schena; DNA microarray; a practical approach, Oxford, 1999).

In addition, the nucleic acid chip for analyzing
15 biological significance of biomolecules in a biosample according to the present invention has a configuration in which capture probes synthesized using information on the analysis single-stranded nucleic acid and the quality control single-stranded nucleic acid are affixed onto the supporter.

20 As long as the nucleic acid chip according to the present invention may analyze the biological significance of an unknown biomolecule with equal or similar accuracy, in view of manufacturing cost of the nucleic acid chip and analysis efficiency, it is preferable to reduce the number of capture
25 probes affixed onto the nucleic acid chip.

The binding information indicates signals generated by complementary binding between the target probes prepared from the analysis single-stranded nucleic acid and the capture probe. Preferably, the binding information means a profile
5 composed of spots corresponding to the capture probes configuring the supporter, and preferably, means a fluorescence intensity as a signal generated from the labeling substance in the single-stranded nucleic acid in the target probe binding to each of the capture probes configuring
10 respective spots. The binding information is a combination of signals of the analysis target probe and the comparison target probe of the target probe. Ultimately, the binding information indicates a distribution state of single-stranded nucleic acids binding to the biomolecules in the biosample,
15 and a distribution state of the biomolecules binding to the single-stranded nucleic acids may be deduced therefrom.

For this reason, the method for preparing a nucleic acid chip according to the present invention may further include reducing the number of capture probes to be affixed onto the
20 nucleic acid chip according to the present invention by analyzing a degree of contribution of each of the capture probes to analyzing biological significance of the biomolecules and selecting the capture probes on the basis of the analyzed degree of contribution in a range in which the
25 biological significance of the biomolecules may be analyzed.

In the case of analyzing a biomolecule using the nucleic acid chip according to the present invention, related data on binding information are accumulated, and a specific single-stranded nucleic acid contributing to analyzing biological significance of the biomolecule may be naturally found therefrom, such that bio markers useful for analyzing biomolecules may be naturally found.

The present invention provides a reference substance, wherein the reference substance is composed of external molecules that are not contained in a biosample, and used for quality control of an analysis process for analyzing biological significance of biomolecules in the biosample as an analysis single-stranded nucleic acid, and for quantitative analysis of the biomolecules contained in the biosample.

The present invention provides a kit for analyzing biomolecules, wherein the analysis single-stranded nucleic acid for analyzing biological significance of the biomolecules in the biosample and the reference substance are used.

The present invention provides an apparatus for analyzing biomolecules, wherein the biomolecules are analyzed by a method for analyzing biomolecules using the analysis single-stranded nucleic acid and the reference substance, and the apparatus has a system for analyzing biomolecules, the system including a sample treating device for preparing biomolecules in the biosample, and an amplification device composed a

module for preparing and amplifying a biomolecule-single-stranded nucleic acid complex and a module for analyzing the amplified product.

In order to more efficiently perform the method for
5 analyzing biomolecules according to the present invention, in an apparatus for analyzing biomolecules using an analysis binding single-stranded nucleic acid and a reference substance, including the sample treating device for separating biomolecules in the sample containing the biomolecules and the
10 amplification device composed of the module for preparing and amplifying the biomolecule-analysis single-stranded nucleic acid and reference-single-stranded nucleic acid complex and the module for analyzing the amplified product, the system according to the present invention may be composed of the
15 sample treating device including a mixing chamber, a lysing chamber, and a reaction chamber, and the amplification device, and the sample treating device and the amplification device may be combined with each other to thereby be used.

Analysis of a sample suspected to contain target
20 biomolecules is accompanied with a series of sample preparing steps, and is performed in a sample treating device composed of the mixing chamber and the lysing chamber. These steps may include filtration, cell lysis, preparation of biomolecules and a biomolecule-single-stranded nucleic acid complex, and
25 mixing with a reagent. In order to have confidence in a

biomolecule analysis result, it is useful to control contamination in a sample preparing process. A method for preparing a sample for a nucleic acid amplification reaction, and for verifying effectiveness of sample preparation may be
5 provided.

The sample is suspected to contain a target entity selected from the group consisting of cells, spores, microorganisms, and viruses, and the target entity contains at least one target biomolecule. The method includes introducing
10 the sample into a device having a mixing chamber for mixing the sample with a sample preparation control. The sample preparation control is selected from the group consisting of cells, spores, microorganisms, and viruses, and contains a quality control substance. The device also includes a lysing
15 chamber and a reaction chamber. The sample is mixed with the sample preparation control with each other in the mixing chamber.

The method also includes: subjecting the sample preparation control and the target entity, if the target
20 entity is present in the sample, to lysis treatment in the lysing chamber to purify the biomolecules; forming the biomolecule-single-stranded nucleic acid complex; exposing the biomolecule-single-stranded nucleic acid complex in the lysing chamber to nucleic acid amplification conditions in the
25 reaction chamber; and detecting the presence or absence of at

least one quality control substance. Positive detection of the quality control substance indicates that the sample preparation process was satisfactory, but it was impossible to detect the quality control substance, which means that the
5 sample was inappropriately prepared.

The present invention provides an amplification device for preparing a sample for a nucleic acid amplification reaction and for verifying effectiveness of sample preparation. The sample is suspected to contain a target
10 entity selected from the group consisting of cells, spores, microorganisms, and viruses, and the target entity contains at least one target biomolecule. The device includes a body having a first chamber accommodating the sample preparation control to be mixed with the sample therein. The sample
15 preparation control is selected from the group consisting of cells, spores, microorganisms, and viruses, and contains the quality control substance.

The body also includes a lysing chamber for subjecting the target entity, if present in the sample, and the sample
20 preparation control to lysis treatment to release biomolecules therefrom and separate the biomolecule-single-stranded nucleic acid complex. Further, the body includes a lysing chamber reacting the released biomolecule and an analysis single-stranded nucleic acid to form a biomolecule-single-stranded
25 nucleic acid complex. The body also includes a reaction

chamber for holding a nucleic acid for amplification and detection.

The device further includes at least one flow controller for guiding the sample mixed with the sample preparation control so as to flow from the first chamber into the lysing chamber and for guiding the biomolecule released in the lysing chamber so as to flow into the reaction chamber.

In some exemplary embodiments, the lysing chamber accommodates an enzyme, at least one filter, and a solid state substance therein, in order to capture the target entity, if present in the sample, and the sample preparation control when the sample flows through the lysing chamber. In addition, the device further includes at least one waste chamber for accommodating used sample fluid that has flowed through the lysing chamber, and the at least one flow controller may also guide the used sample fluid that has flowed through the lysing chamber so as to flow into the waste chamber.

In some exemplary embodiments, the device further includes an ultrasonic transducer coupled to a wall of the lysing chamber to sonicate the lysing chamber. In some exemplary embodiments, the device further includes beads in the lysing chamber for rupturing the sample preparation control and the target entity.

According to another aspect of the present invention, there is provided a method for determining effectiveness of a

lysis process. This method includes mixing a sample suspected to contain a target entity selected from the group consisting of cells, spores, microorganisms, and viruses with a sample preparation control. The target entity contains at least one
5 quality control substance. The sample preparation control is selected from the group consisting of cells, spores, microorganisms, and viruses, and contains the quality control substance. A mixture of the sample preparation control and the target mixture, if present in the sample, is subjected to
10 lysis treatment. The method further includes detecting the presence or absence of the quality control substance so as to determine whether or not biomolecules are released from the sample preparation control during the lysis treatment. Positive detection of the quality control substance indicates
15 that the sample preparation process was satisfactory, but it was impossible to detect the quality control substance, which means that the sample was inappropriately prepared.

In some exemplary embodiments, the method includes allowing the sample mixed with the sample preparation control
20 to flow through the chamber accommodating the solid-phase substance therein, in order to allow the sample preparation control and the target entity, if present in the sample, to be captured by the solid phase material, prior to the lysis treatment.

25 In some exemplary embodiments, the sample may be pre-

filtered before the sample is mixed with the sample preparation control. In some exemplary embodiments, lysis treatment includes exposing the sample preparation control and the target entity to ultrasonic energy. In some exemplary
5 embodiments, lysis treatment also includes agitating beads for rupturing the sample preparation control and the target entity. In some exemplary embodiments, the sample preparation control is a spore. In some exemplary embodiments, the mixing includes dissolving a dried bead containing the sample
10 preparation control.

In some exemplary embodiments, lysis treatment includes contact with a chemical lysis agent. In some exemplary embodiments, a marker nucleic acid sequence is detected by amplifying the marker nucleic acid (for example, by PCR) and
15 detecting the amplified marker nucleic acid sequence. In some exemplary embodiments, the amplified marker nucleic acid sequence is detected by determining if a signal from a probe capable of binding to the marker nucleic acid sequence exceeds a threshold value.

20 A reaction mixture in a reaction chamber of a reaction vessel of the amplification device is exposed to nucleic acid amplification conditions. Amplification of an RNA or DNA template using reactions is well known [U.S. Patent Nos. 4,683,195 and 4,683,202; PCR Protocols: A Guide to Methods and
25 Applications (Innis et al., eds, 1990)]. Amplification of DNA

involves repeated cycles of heat-denaturing the DNA, annealing two oligonucleotide primers to sequences flanking the DNA segment to be amplified, and extending the annealed primers with DNA polymerase. The primers hybridize to opposite
5 strands of a target sequence and are oriented so that DNA synthesis by the polymerase proceeds across the region between the primers, thereby effectively doubling the amount of the DNA segment. Moreover, because the extension products are also complementary to and capable of binding to primers, each
10 successive cycle essentially doubles the amount of DNA synthesized in the previous cycle. This results in the exponential accumulation of the specific target fragment, at a rate of approximately 2^n (here, n is the number of cycles). Methods such as the amplification reaction and ligase chain
15 reaction (LCR) may be used to directly amplify nucleic acid sequences. Isothermic amplification reactions are also known and may be used according to the methods of the invention.

The nucleic acid amplification reaction is preferably carried out using a thermal processing instrument that heats
20 and/or cools the reaction mixture in the reaction vessel to the temperatures needed for the amplification reaction. The thermal processing instrument as described may also include one or more detection mechanisms for detecting a marker nucleic acid sequence of the sample preparation control and
25 one or more target nucleic acid sequences for which the sample

is being tested. A preferable thermal processing instrument embedded with optical detectors for amplifying and detecting nucleic acid sequences in the reaction vessel (U.S. Patent Nos. 6,369,893 and 6,391,541,) may be used. In addition,
5 there are also many other known methods for controlling a temperature of a reaction mixture and detecting nucleic acid sequences in the reaction mixture that are suitable for the present invention.

Further, it is preferable that detection of the quality
10 control substance of the sample preparation control and detection of one or more quality control substances for which the sample is being tested is carried out using probes. It is preferable that the reaction vessel has one or more transparent or light-transmissive walls through which signals
15 from the probe may be optically detected. Preferably, capture probes may be used to detect and quantify the nucleic acid sequences. There are many different types of assays that employ nucleic acid capture probes. Some of these capture probes generate signals with a change in the fluorescence of a
20 fluorophore due to a change in its interaction with another molecule or moiety.

As another method for detecting amplification products, a fluorogenic probe consists of an oligonucleotide labeled with a fluorescent reporter dye module. Cleavage of the capture
25 probe generates an increase in the fluorescence intensity of

the reporter dye.

In order to confirm detection of a target biomolecule in a sample or absence thereof, there is a need to remove contamination of sample preparation. This is the reason why a sample preparation control should be subjected to the same treatment as a target entity (for example, a target cell, a spore, a virus, or a microorganism, containing biomolecules) in a sample. When the quality control substance of the sample preparation control is detected, sample preparation is considered to be satisfactory. When it is impossible to detect the presence of the quality control substance, sample preparation is considered to be inappropriate, and a test result for a target nucleic acid sequence is considered to be "undetermined". Preferably, the presence or absence of the quality control substance is detected by determining whether or not a signal from the capture probe capable of binding to the target probe exceeds a limit value, for example, a predetermined fluorescence limit value that needs to be satisfied or exceed in order to consider an analysis method to be effective.

A fluid control device may be controlled by a computer according to a desired protocol. In the case of using a single value, since a failure factor is only one, a high preparation yield may be obtained. A compact device (for example, a small cartridge form) may be obtained by

integration of fluid control and treatment constitution members, which may facilitate automation of molding and assembly. As described above, it may be advantageous that this system has dilution and mixing capability, intermediate
5 wash capability, and positive pressurization capability. A fluid path in the system is generally closed, in order to minimize contamination of the fluid in the system and to facilitate accommodation and control of the fluid. The reaction vessel is conveniently detachable and replaceable,
10 and may be disposable in some embodiments.

The present invention provides a method and an apparatus for analyzing biomolecules, wherein a configuration for analyzing biological significance using data on binding information on the biomolecules and analysis single-stranded
15 nucleic acids includes: a module for receiving data on binding information between the biomolecules and the analysis single-stranded nucleic acids in a patient group and binding information between the biomolecules and the analysis single-stranded nucleic acids in a control group to construct
20 databases; a module for performing pre-processing in an analysis system using the received data on binding information; a module for generating a patient model using the pre-processed result; a module for loading the generated model and applying the loaded model to a visiting patient to perform
25 diagnosis corresponding to a blind test; and a module for

evaluating performance of the system through cross validation.

In the present invention, a system for predicting biological significance using data on binding information on the biomolecules and the analysis single-stranded nucleic acids may be used, for example, in diagnosis, but is not limited thereto.

The data on binding information on various biomolecules and analysis single-stranded nucleic acids, generated according to the present invention, may generate various information associated with cells, tissue, or diseases, which are a huge amount of information having high-level characteristics. In the module for performing pre-processing in the analysis system using the received data, a multivariate analysis method for searching features affecting a state of a patient and improving classification performance is a feature selection method for searching important variables for accurate diagnosis and treatment to search main features through dimensional reduction or characteristics modification.

As the feature selection method, there is an unsupervised learning method or a supervised learning method depending on whether or not class information is used in learning. In principal component analysis (PCA) or independent component analysis (ICA) mainly used in the unsupervised learning method, features may be extracted in consideration of characteristics of variables. The supervised learning method

is a method for selecting a variable by utilizing statistical significance between class information and variables or correlations between the variables. In this method, main features may be extracted through performance applied to a
5 classifier while sequentially adding features to a given feature set or removing the features from the given feature set in a forward or backward direction.

A module for performing learning to generate a patient model using the pre-processed result performs a procedure of
10 classifying the selected features depending on class through a suitable classifier.

In the present invention, an artificial neural network is used, and since behaviors are determined depending on input and output, the artificial neural network has been applied in
15 various fields such as pattern recognition, function approximation, classification methods, and the like. A structure of the artificial neural network is composed of a plurality of layers, nodes, and neural connection weights. A neural inter-connection method used in the present invention
20 is a feed-forward method. An output value is calculated using the neural connection weight and an activation function for each node depending on an input pattern. When specific work is processed using the generated binding information, in the case in which an estimated value and an actual value are
25 different from each other, a method of repeating a process of

reducing an error while comparing a calculated value with an actual result value is the feed-forward method.

The present invention provides a method and an apparatus for analyzing biomolecules, wherein a method for selecting the
5 patient model is selected from the group consisting of linear model methods, support vector machine methods, neural network methods, classification and regression tree methods, ensemble learning methods, discriminant analysis methods, a nearest neighbor method, Bayesian network methods, and independent
10 components analysis methods.

In most of the diseases of which accurate and comprehensive mechanisms are not found, diagnosis based on cases is significantly important. However, in an existing case based a machine learning and reasoning system designed
15 only based on a specific machine learning technique, accuracy is low, such that the development for an improved system is continuously required. Further, the existing system is designed only as a discriminator of disease, using all learned clinical test items, and a method for utilizing importance or
20 the order of priority of the clinical test items depending on the kind of disease is not provided.

The present invention, which relates to a system for diagnosing a disease and selecting test items using a case based a machine learning and reasoning technology for
25 supporting accurate disease diagnosis by a doctor, relates to

a system for analyzing test information of a novel patient using a discriminator of disease to identify a disease, and providing the minimum test items required for finally identifying each disease by preliminary diagnosis, wherein the
5 discriminator is a machine learner using a artificial neural network trained through case databases on patients. In the method for diagnosing a disease through machine learning and reasoning, the machine learning technique is individually applied. As a method for selecting the patient model, there
10 are linear model methods, support vector machine methods, neural network methods, classification and regression tree methods, ensemble learning methods, discriminant analysis methods, a nearest neighbor method, Bayesian network methods, independent components analysis methods, and the like.

15 In view of configuration and actual application, the present system may be divided into two systems. That is, the present system may be divided into a stand-alone diagnosis system only for diagnosis and an integration system linked with existing hospital information systems, that is, an order
20 communication system (OCS), a picture archiving and communication system (PACS), a laboratory information system (LIS), and the like. For cooperation with the integration system, a system needs to be configured based on HL& and DICOM standards. The present system is in cooperation with a
25 patient monitoring system (PMS) as an early model, thereby

increasing accuracy of diagnosis. In addition, the present system may be developed as a system in cooperation with various medical information systems such as OCS, electronic medical record (EMR), PACS, and the like, as well as PMS, 5 thereby making it possible to develop a more accurate diagnosis system including various disease factors.

The present invention provides a method for analyzing biomolecules using analysis single-stranded nucleic acids and a reference substance, wherein a biosample is selected from 10 the group consisting of bacteria, fungi, viruses, cell lines, and tissue, and the biomolecule is at least one selected from the group consisting of proteins, carbohydrates, lipids, polysaccharides, glycoproteins, hormones, receptors, antigens, antibodies, and enzymes.

15

Mode for Invention

Hereinafter, a method for preparing a reference substance and a biochip according to the present invention, and a method for analyzing biomolecules in a biosample 20 composed of two or more biomolecules using the same will be described in detail with reference to accompanying drawings and Examples. The following Examples are provided for illustrative purposes, but should not be construed as limiting the scope of the present invention.

25

Example 1. Preparation of Single-stranded Nucleic Acid
Having Random Base Sequence

Polymerase chain reaction (PCR) was performed using single-stranded DNA oligonucleotides having the following
5 random base sequence to prepare double-stranded DNAs, followed by in vitro transcription of the double-stranded DNAs, thereby preparing a single-stranded RNA library (random single-stranded nucleic acids).

00875'-GGGAGAGCGGAAGCGTGCTGGGCC N40

10 CATAACCCAGAGGTCGATGGATCCCCC-3' (Here, underlined base sequences are invariable regions and N40 means sequence sites at which bases such as adenine (A), guanine (G), thymine (T), cytosine (C), and the like, are randomly present at respective positions.)

15 A forward (FW) primer used in PCR may form base pairing with 5'-terminals of the underlined bases of the above base sequence, and include a promoter base sequence for RNA polymerase of bacteriophage T7.

A reverse (RE) primer used in the PCR may form base
20 pairing with 3'-terminals of the underlined bases of the above base sequence. In addition, the FW and RE primers may contain base sequences (restriction enzyme cleavage sites) for EcoRI, BamHI, and the like, respectively, for subsequent cloning.

25 Random single-stranded nucleic acids to be reacted

with a biosample constitute an RNA library containing 2'-F-substituted pyrimidines. In addition, DNA library transcripts and PCR primers were designed as described above and prepared by PCR and in vitro transcription.

5 PCR was performed with 1,000 pmoles of single-stranded DNA serving as a template, in the presence of 2,500 pmoles of a pair of PCR primers (5P7) in a buffer solution containing 50 mM KCl, 10 mM Tris-Cl (pH 8.3), 3 mM MgCl₂, 0.5 mM dNTP (dATP, dCTP, dGTP, and dTTP), and 0.1 U Taq DNA
10 Polymerase (Perkin-Elmer, Foster City Calif.), followed by purification of the PCR product through QIAquick-spin PCR columns (QIAGEN Inc., Chatsworth Calif.).

Single-stranded nucleic acids containing 2'-F-substituted pyrimidines were synthesized through in vitro
15 transcription, and purified. 200 pmoles of double-stranded DNAs, 40 mM Tris-Cl (pH 8.0), 12 mM MgCl₂, 5 mM DTT, 1 mM spermidine, 0.002% Triton X-100, 4% PEG 8000, 5 U T7 RNA Polymerase, ATP and GTP (each 1 mM), and 2'-F-CTP and 2'-F-UTP (each 3 mM) were reacted at 37°C for 6 to 12 hours,
20 followed by purification through a Bio-Spin 6 chromatography column (Bio-Rad Laboratories, Hercules Calif.). Amounts and purities of the purified nucleic acids were analyzed using a UV spectrometer.

25 Example 2. Preparation of Biomolecule-binding Single-

stranded Nucleic Acid Binding to Human Serum Protein

2-1. Securing of Biomolecule-Single-stranded Nucleic Acid Complex

2-1-1. Washing Method

5 In the present invention, a biosample composed of two or more biomolecules was an example of human serum proteins. A solution containing the random single-stranded nucleic acids synthesized in Example 1 at a concentration of 10^{15} base sequences/L was added in an amount of 200 pmol/L to a
10 selection buffer (50 mM Tris-Cl (pH 7.4), 5 mM KCl, 100 mM NaCl, 1 mM $MgCl_2$, and 0.1% NaN_3), heated at $80^\circ C$ for 10 minutes, and allowed to stand on ice for 10 minutes. A reaction solution was prepared by adding yeast tRNA (Life Technologies) in an amount five times as much as the used
15 single-stranded nucleic acids and 0.2% bovine serum albumin (BSA, Merck) thereto.

After 10 μL of a serum biosample containing an external reference substance was added to 90 μL of the reaction solution, a nitrocellulose membrane disc was
20 soaked therein, and a reaction was performed for 30 minutes with shaking. The disk to which the serum biosample was attached was treated with the prepared RNA single-stranded nucleic acids and a reaction was performed for 30 minutes.

After reaction, unbound RNA single-stranded nucleic
25 acids were removed by repeating a washing process with a

washing buffer as described below, such that human serum protein (biomolecule)-single-stranded nucleic acid complexes to be used to prepare single-stranded nucleic acids binding to human serum proteins of the human serum biosample were secured by a single selection process.

As the washing buffer for securing the biomolecule-single-stranded nucleic acid complexes, 0 to 1× SELEX buffer or 0 to 500 mM EDTA solution was used. Reverse transcription (RT)-PCR was performed on the secured complexes, thereby amplifying and preparing a DNA pool directing RNAs (biomolecule-binding single-stranded nucleic acids) binding to the serum proteins. Here, the selection and amplification process may be repeated several times to prepare biomolecule-binding single-stranded nucleic acids. Further, in order to prepare single-stranded nucleic acid binding to the external reference substance, an external reference substance-single-stranded nucleic acid complex may be secured together with the human serum protein-single-stranded nucleic acid complexes.

In addition, the secured RT-PCR product, DNA, was cloned into plasmids to secure individual clones, thereby completing preparation of the biomolecule-binding single-stranded nucleic acids. The plasmids were separated and used to determine base sequences of the single-stranded nucleic acids binding to the biomolecules.

Base sequences of capture probes to be used in a biochip for generating profiles of biomolecules according to the present invention were designed using information on the base sequences of the single-stranded nucleic acids binding to the human serum proteins (biomolecules). Thus, in order to select the single-stranded nucleic acids and prepare the capture probes, after confirming secondary structures and the free energies of the secondary structures using a MFOLD program for modeling secondary structures of nucleic acids, single-stranded nucleic acids having the most stable secondary structures were selected, and the capture probes were also designed on the basis of the selected single-stranded nucleic acids.

As the external reference substance, after five plant-specific proteins were selected and proteins corresponding thereto were expressed using an E. coli expression system, the expressed proteins were separated, and a single-stranded nucleic acid binding to the external reference substance was secured by SELEX. A capture probe corresponding to the external reference substance was designed using a base sequence of the secured single-stranded nucleic acid.

2-1-2. Capillary Electrophoresis

A solution containing the synthesized random single-

stranded nucleic acids at a concentration of 10^{15} base sequences/L was added in an amount of 200 pmol/L to a reaction solution (100 mM Tris-HCl (pH 8.2), 200 mM NaCl, and 10 mM $MgCl_2$), heated at $80^{\circ}C$ for 10 minutes, and allowed
5 to stand on ice for 10 minutes. A reaction solution was prepared by adding yeast tRNA (Life Technologies) in an amount five times as much as the used single-stranded nucleic acids and 0.2% bovine serum albumin (BSA, Merck) thereto.

10 10 μ l of a serum biosample was added to 90 μ l of the reaction solution and a reaction was carried out for 30 minutes. The reaction mixture solution was subjected to capillary electrophoresis using a buffer solution (50 mM Tris-HCl, pH 8.2). All analyses using the capillary
15 electrophoresis in the present invention were performed using a P/ACE 5000 CE-LIF system (Beckman Coulter) equipped with fused-silica capillary (Beckman Coulter; length of 37 cm, inner diameter of 75 μ m). A fluorescent substance was excited by a 3 mW Ar-ion laser (488nm) attached to the
20 system to emit signals through a 520 nm filter, and the signals were detected by a detector in the LIF system.

All solutions used in the analysis and capillary treatment were filtered through a filter having pore size of 0.2 μ m. The capillary tubes were washed by flowing 1 N
25 NaOH and distilled water for 5 minutes therein,

respectively, and then used, and between runs, sequentially washed with 1 N NaOH, distilled water, and the buffer solution for 2 minutes each.

Electrophoresis was performed by applying a voltage of 5 10.8 kV thereto, and the results were analyzed. It was confirmed through a graph obtained by analyzing formation of the biomolecule-single-stranded nucleic acid complex using capillary electrophoresis that the biomolecule-single-stranded complex was specifically formed and 10 separated.

RT-PCR was performed on the separated complex, thereby amplifying and preparing a DNA pool directing RNAs (biomolecule-binding single-stranded nucleic acids) binding to the serum proteins. Here, the selection and 15 amplification process may be repeated several times to prepare biomolecule-binding single-stranded nucleic acids.

2-1-3. Structure of nitrocellulose and nylon

A solution containing the synthesized random single- 20 stranded nucleic acids at a concentration of 10^{15} base sequences/L was added in an amount of 200 pmol/L to a reaction solution (100 mM Tris-HCl (pH 8.2), 200 mM NaCl, and 10 mM $MgCl_2$), heated at 80°C for 10 minutes, and allowed to stand on ice for 10 minutes. A reaction solution was 25 prepared by adding yeast tRNA (Life Technologies) in an

amount five times as much as the used single-stranded nucleic acids and 0.2% bovine serum albumin (BSA, Merck) thereto.

10 μ l of a serum biosample was added to 90 μ l of the
5 reaction solution and the prepared RNA single-stranded nucleic acids were reacted for 30 minutes, thereby forming biomolecule-single-stranded nucleic acid complexes.

In order to select biomolecule-binding single-stranded nucleic acids binding to a human serum biosample
10 (biomolecules), when the reaction mixture solution was treated with a structure made of nitrocellulose and nylon and a pressure was applied thereto, the single-stranded nucleic acid complexes were present on a nitrocellulose filter, and unbound single-stranded nucleic acids were
15 present on a nylon membrane. The human serum protein (biomolecule)-single-stranded nucleic acid complexes were secured through a single selection process by collecting the nitrocellulose filter and repeating a washing process with various washing buffers to remove the unbound single-
20 stranded nucleic acids present on the nitrocellulose filter.

As the washing buffer for securing the biomolecule-single-stranded nucleic acid complexes, 0 to 1× SELEX buffer or 0 to 500 mM EDTA solution was used. RT-PCR was performed on the secured complexes, thereby amplifying and
25 preparing a DNA pool directing RNAs (biomolecule-binding

single-stranded nucleic acids) binding to the serum proteins. Here, the selection and amplification process may be repeated several times to prepare biomolecule-binding single-stranded nucleic acids.

5

2-2. Preparation of Biomolecule-Binding Single-stranded Nucleic Acids

RT-PCR was performed on the secured complexes, thereby amplifying and preparing a pool of DNAs directing RNAs
10 (biomolecule-binding single-stranded nucleic acids) binding to the serum proteins. Here, the selection and amplification process may be repeated several times to prepare biomolecule-binding single-stranded nucleic acids.

The secured RT-PCR product, DNA, was cloned into
15 plasmids to secure individual clones, thereby completing preparation of the biomolecule binding-single-stranded nucleic acids. The plasmids were separated and used to determine base sequences of the biomolecule-binding single-stranded nucleic acids.

20 Base sequences of capture probes to be used in a nucleic acid chip for generating profiles of biomolecules according to the present invention were designed using information on base sequences of the single-stranded nucleic acids binding to the human serum proteins
25 (biomolecules). Thus, in order to select the single-

stranded nucleic acids and prepare the capture probes, after confirming secondary structures and the free energies of the secondary structures using a MFOLD program for modeling the secondary structures of nucleic acids, single-
5 stranded nucleic acids having the most stable secondary structures were selected, and the capture probes were designed on the basis of the selected single-stranded nucleic acids.

The secured RT-PCR product, DNA, was cloned into
10 plasmids to secure individual clones, thereby completing preparation of the biomolecule binding-single-stranded nucleic acids. The plasmids were separated and used to determine base sequences of the biomolecule-binding single-stranded nucleic acids.

15 Base sequences of capture probes to be used in a nucleic acid chip for generating profiles of biomolecules according to the present invention were designed using information on base sequences of the single-stranded nucleic acids binding to the human serum proteins
20 (biomolecules). Thus, in order to select the single-stranded nucleic acids and prepare the capture probes, after confirming secondary structures and the free energies of the secondary structures using a MFOLD program for modeling the secondary structures of nucleic acids, single-
25 stranded nucleic acids having the most stable secondary

A reference substance was composed of five kinds of plant specific proteins A, B, C, D, and E secured from the plant specific database

[Table 1]

Kind	Locus)	Content	Accession number
A	At1g65390.1	defense/immunity protein	GO:0003793
B	At5g39310.1	cell elongation	GO:0009826
C	At4g15910.1	Drought-Induced Protein (Di21)	GO:0009414
D	At1g12860.1	Bhlh Protein	GO:0003677
E	At4g02530.1	Chloroplast Thylakoid Lumen Protein	GO:0009543

90

Schneider, S.R. Eddy, C. Tuerk, L. Green, S. Macdougall, and D. Tasset. 1993. RNA: the shape of things to come, pp. 497-510. In: R.F. Gestelend and J.F. Atkins (eds.). The RNA World, Cold Spring Harbor Press, Cold Spring Harbor, N.Y.).

5 The obtained single-stranded nucleic acids were referred to as quality control single-stranded nucleic acids, and capture probes corresponding to the quality control single-stranded nucleic acids were designed using base sequences of the quality control single-stranded nucleic acids.

10

Example 4. Preparation of Biochip (Nucleic Acid Chip)

As capture probes to be affixed onto a surface of a glass slide, single-stranded nucleic acids (oligonucleotides) having base sequences complementary to
15 those of the approximately 3,000 biomolecules binding single-stranded nucleic acids selected in Example 1 and the quality control single-stranded nucleic acids were organically synthesized (Bioneer, Korea), thereby preparing the capture probes.

20 A nucleic acid chip was prepared on which the capture probes were arranged in a constant order using an UltraGAPSTM Coated Slide (Corning Inc.), a gamma amino propyl silane (GAPS)-coated glass slide. The nucleic acid chip was manufactured using a microarrayer system (GenPak)
25 operating in a pin type while the spot spacing of the

arrays was set to be 370 μm center-to-center. Each of the capture probes were dissolved in a standard solution, thereby adjusting a concentration thereof. In this case, a humidity of 70% was maintained inside the arrayer system while it performed spotting. After being kept in a humidified chamber for 24 to 48 hours, the spotted slides were baked in a UV crosslinker. After the capture probes were fixed to the glass slides using a widely known method, the slides were dried by centrifugation and stored in a light-tight place.

Example 5. Preparation of Target Probe

The same amounts of plasmids in which the single-stranded nucleic acids prepared in Example 1 and used to prepare the biochip (nucleic acid chip) were inserted, and plasmids into which the quality control single-stranded nucleic acids prepared in Example 3 were inserted were mixed with each other, thereby preparing a plasmid pool. In addition, a pool of the single-stranded nucleic acids binding to human serum proteins, or the like, was prepared as described below through PCR and in vitro transcription after designing and preparing the plasmid pool and PCR primers.

PCR was performed for 30 cycles of 30 seconds at 94°C, 30 seconds at 52°C, and 20 seconds at 72°C in a PCR reaction

solution containing 100 pM 5'-primers, 100 μ M 3'-primers and a dNTP mixture (5 mM DATP, 5 mM CTP, 5 mM dGTP, and 5 mM dTTP) using 1 pg of the plasmid pool as a transcript by a standard PCR method to synthesize double-stranded nucleic acids, followed by purification through a QIAquick-spin PCR column (QIAGEN Inc., Chatsworth Calif.).

Single-stranded nucleic acids of RNA molecules containing 2'-F-substituted pyrimidines were synthesized through in vitro transcription, and purified.

10 200 pmoles double-stranded DNAs, 40 mM Tris-Cl (pH 8.0), 12 mM MgCl₂, 5 mM DTT, 1 mM spermidine, 0.002% Triton X-100, 4% PEG 8000, 5 U T7 RNA Polymerase, ATP and GTP (each 1 mM), and 2'-F-CTP and 2'-F-UTP (each 3 mM) were reacted at 37°C for 6 to 12 hours, followed by purification
15 through a Bio-Spin 6 chromatography column (Bio-Rad Laboratories, Hercules Calif.).

A reference substance I in which different amounts of the reference substances were contained was added to a phosphate buffered saline (PBS) solution. The reference
20 substance I was composed of five kinds of plant specific proteins, biomolecules A, B, C, D, and E (see Table 1). The reference substance I was composed of the external biomolecule A (0.01 pg/ml), the external biomolecule B (1.0 pg/ml), the external biomolecule C (100.0 pg/ml), the
25 external biomolecule D (10.0 ng/ml), and the external

molecule E (1.0 µg/ml).

The human serums used in analysis were serums taken from a healthy person and a cardiovascular disease patient, stable angina pectoris patient, and a biosample was
5 prepared by adding 10 µl of serum biosample to 90 µl of the PBS solution to which the reference substance I was added, and putting a nitrocellulose membrane disc thereinto to perform a reaction for 30 minutes while shaking. 100 to 400 ng of the single-stranded nucleic acids prepared above
10 were added thereto, and reactions were performed for 30 minutes, thereby forming biomolecule-single-stranded nucleic acid complexes.

The prepared single-stranded nucleic acids were treated with the disk to which the serum biosample
15 containing the reference substance I was attached, thereby performing a reaction for 30 minutes. The resultant was washed with a selection buffer or 50 mM EDTA three times, and the disc to which protein-single-stranded nucleic acids were attached was separated and collected.

20 After the collected disc to which the protein (biomolecule)-single-stranded nucleic acids were attached, or a disc to which the external reference substance as an analysis target probe and the protein (biomolecule)-single-stranded nucleic acids were attached was added to a RT-PCR
25 solution to perform reverse transcription, an amplification

reaction was performed thereon using a Cy-5 labeled primer (5'-Cy5-CGGAAGCGTGCTGGGCC-3'), thereby preparing an analysis target probe, a Cy-5 labeled single-stranded nucleic acid. Reverse transcription was performed by the same method as described above using the single-stranded nucleic acids prepared from the plasmid pool obtained by mixing the same amounts of the plasmids for the serum proteins and the plasmids for the external reference substance with each other,, and an amplification reaction was performed using a Cy-3 labeled primer (5'-Cy3-CGGAAGCGTGCTGG GCC-3'), thereby preparing a comparison target probe, a Cy-3 labeled single-stranded nucleic acid. The two solutions were mixed with each other in the same amounts, thereby preparing a target probe containing the analysis target probe and the comparison target probe.

Example 6. Hybridization Reaction of Biochip (Nucleic Acid Chip) and Target Probe Solution

The target probe solution prepared in Example 4 was treated with the capture probe of the biochip (nucleic acid chip) of the present invention to thereby be hybridized at 60°C for 4 to 12 hours, and then washed with 0.1 x SSC solution at 42°C. Here, a hybridization solution contained 1 M sodium chloride, 0.3 M sodium citrate, 0.5% SDS or 100 /ml salmon sperm DNA, and 0.2% bovine serum albumin or

single-stranded nucleic acids.

After completion of pre-hybridization, the glass slide was treated with the target probe solution prepared in Example 3 to conduct hybridization at 42°C for 12 hours, followed by washing the nucleic acid chip with washing solutions. Here, compositions of the washing solutions were sequentially 1×SSC+0.2% SDS, 1×SSC+0.2% SDS, 0.5×SSC+0.2% SDS, and 0.01×SSC+0.2% SDS, and the washing was performed at 42°C for 30 minutes for each solution.

10

Example 7. Search and Analysis of Spots on Biochip (Nucleic Acid Chip)

After completion of the washing in Example 6, the glass slide was dried by centrifugation and scanned with a laser scanner (GenePix4000, Axon Corp.) using laser light of a wavelength (635nm) suitable for exciting a fluorescent dye (Cy5). Fluorescent images were captured as multi-image-tagged image file format and analyzed with a suitable image analysis software (GenePix Pro 3.0, Axon).

20 Signal intensity per spot (unit: quanta) from which basic signals of a neighboring background (that is, background signals) were subtracted was used. Here, the term "background signals" means signals of a local background consisting of four spots neighboring a specific spot. Generally, when 90% or more pixels of the spot have

25

a signal intensity over background signal+2 standard deviations (S. D.), the spot is used for data analysis; otherwise, the spot is classified as a bad spot and is not used for data analysis.

5 Signal intensity was normalized against variations according to labeling efficiency using internal standard (IS) signals (e.g., Normalized Intensity=Probe Intensity/IS intensity). In the case of monolabeling, the signal intensity of Cy5 channels was recorded, and in the case in
10 which spotting is conducted two times or more, mean values were used. For the signal intensity (S) of target single-stranded nucleic acid, signal intensity of each of the spot pixels was measured and a median value thereof (median value of pixel-by-pixel) was used. The signal intensity
15 (S) was normalized against variations according to labeling efficiency using internal standard (IS) signals.

$$S'(\text{normalized value}) = S(\text{Cy5-reference}) \times (\text{Cy5-IS}).$$

Relationships between analysis results of pixel density and actual sample amounts were found by the method
20 as described above, thereby making it possible to confirm the correlation therebetween. It is possible to provide a method for converting the fluorescent data of the nucleic acid chip into image and confirming a profile of biomolecules in a biosample in all spot patterns. The spot
25 patterns may be analyzed by a method such as a hierarchical

clustering method, an artificial neural network method, and the like, and then used. Fluorescent intensities of spots may vary depending on properties of double strands formed between the capture probes and the target probes. The
5 fluorescent intensity of the spot may be determined depending on amounts of the analysis target probe and the comparison target probe configuring the spot.

First, fluorescent images according to Example 7 were shown in FIG. 6, and the reference substance was composed
10 of five kinds of plant specific proteins, that is, the external biomolecules A, B, C, D, and E. The external biomolecule A (0.01 pg/ml), the external biomolecule B (1.0 pg/ml), the external biomolecule C (100.0 pg/m), the external biomolecule D (10.0 ng/ml), and the external
15 molecule E (1.0 µg/ml) were added to the serum sample and analyzed. Fluorescent intensity of a spot corresponding to the reference substance will be determined by amounts of a quality control comparison target probe and a quality control analysis target probe. Since the amount of the
20 quality control comparison target probe is known, the fluorescent intensity of the spot corresponding to the reference substance will be determined by the amount of the quality control analysis target probe to be formed from the reference substance in an analysis biosample. That is, the
25 fluorescent intensity of the spot corresponding to the

reference substance is associated with the amount of the reference substance contained in the analysis biosample. Therefore, a desired spot may be quantitatively analyzed using a fluorescent intensity of the desired spot by
5 constructing a standard curve of correlation therebetween.

In the present experiment, since the amount of the analysis target probe was constant, the fluorescent intensity of the spot indicated the amount of the analysis target probe, and the amount of the analysis target probe
10 indicated an amount of the human serum protein-single-stranded nucleic acid complex. Further, the amount of the complex indicated an amount of the biomolecules in the biosample. Therefore, it was possible to confirm an amount of a specific biomolecule in the biosample containing the
15 biomolecules corresponding to the spots from the fluorescent intensities of the spots. As a result, a profile of the serum proteins in the human serum may be confirmed by analyzing fluorescent intensities of the formed spots and confirming all spot patterns of the
20 nucleic acid chip.

That is, spectra of blue-yellow-red colors were shown in the formed spots, which was a phenomenon resulting from various ratios between the Cy-3 labeled competitive inhibitor and the cy-5 labeled target probe, both bound to
25 the capture probes. Because the color intensity detected

at a specific spot represents an amount of a specific biomolecule (protein) present in the human serum biosample, configuring the human serum, the image data formed from the color spectra of all spots on the nucleic chip correspond
5 to profiles of biomolecules in a specific biosample.

In more detail, in the method for analyzing biomolecule according to the present invention, a target probe binding to a capture probe to form a double strand at a specific spot is composed of a Cy-3 labeled comparison
10 target probe and a Cy-5 labeled analysis target probe, wherein the former is present in a constant amount, but the latter is present in an amount proportional to that of a biomolecule corresponding thereto in a human serum. Accordingly, a specific spot appears blue when the Cy-5
15 analysis target probe is present in a relatively small amount, yellow when the Cy-3 comparison target probe and the Cy-5 analysis target probe are present in similar amounts, and red when the Cy-5 analysis target probe is present in a relatively large amount.

20 The fluorescent intensity of spots on the nucleic acid chip varies depending on the number of analysis target probes within the double strands, which is correlated with the number of biomolecules. Therefore, the image data reflecting the color spectra of all spots configuring the
25 nucleic acid chip of the present invention may provide

profiles for the biomolecules of the biosample including unknown biomolecules.

The test results as described above are shown in FIG. 6. As shown in FIG. 6, in the glass slide to which the capture probes were attached, color spectra of blue-yellow-red colors were shown at various fluorescent intensities at spots onto which the capture probes, based on the single-stranded nucleic acids binding to serum proteins, were affixed.

10 Example 8. Preparation of Solution Array Using Beads and Generation of Profile

Beads were made of one selected from the group consisting of polystyrene, polymethyl methacrylate, latex, silica, polyvinyltoluene, a styrenevinyltoluene polymer, and a styrene-butadiene polymer. In addition, a size of the micro-beads was not limited, and both a bead having an unmodified surface and a bead having a surface modified with a carboxylic group may be used.

For fixation, the surface of the micro-bead was modified with the carboxylic group, and the capture probe was fixed using an N-hydroxy succinimide (NHS)/1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC) reaction.

As capture probes to be affixed onto surfaces of the beads, single-stranded nucleic acids (oligonucleotides) having base sequences complementary to those of the

approximately 3,000 biomolecules binding single-stranded nucleic acids selected in Example 1 and the quality control single-stranded nucleic acid were organically synthesized (Bioneer, Korea), thereby preparing the capture probes.

5

8-1. Manufacturing of Bead Array

A bead array was manufactured by affixing the capture probes onto respective prepared beads (xMAP carboxylated microspheres; Luminex Corp. Austin, TX) using the capture
10 probes.

Each of the capture probes was prepared at a concentration of 100 μ M by dissolving the capture probes prepared in Example 4 in distilled water. After beads to be reacted were well mixed in numerical order, each 40 μ l
15 was pelleted to a freshly prepared tube (beads denoted by different numbers were prepared depending on respective probes and well-mixed, and for reactions with the probes, each 40 μ l was pelleted and injected into a new tube in a state in which the beads were well-mixed.). 20 μ l of 0.1 M
20 MES buffer (pH 4.5) was mixed therewith, and 2 μ l of the prepared probe was mixed with the beads. Thereafter, 1 μ l of freshly prepared 10 mg/ml 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC) hydrochloride (HCl) solution (Pierce) was added thereto, and a reaction was
25 carried out. The reaction was carried out by appropriately

shaking the mixture for about 30 minutes in the dark. Again, 1 μ l of freshly prepared 10 mg/ml EDC solution was additionally added thereto, followed by further reacting for about 20 minutes. Then, 500 μ l of 0.020 % Tween-20
5 solution was added to each tube and well-mixed. The bead in each tube was centrifuged to remove a supernatant from the tube, and 500 μ l of 0.1% sodium dodecyl sulfate (SDS) solution was added to the tube again, followed by agitating well. The bead in each tube was centrifuged again as
10 described above to remove a supernatant from the tube. Next, the resultant bead was dissolved in 150 μ l of TE buffer (pH 8.0) and stored at 4°C in the dark.

8-2. Formation of Profile

15 An analysis target probe was prepared by the same manner as in Example 5 except that the analysis target probe was a biotin labeled single-stranded nucleic acid prepared by performing an amplification reaction using a biotin labeled primer (5'-biotin-CGGAAGCGTGCTGGGCC-3').

20 The prepared analysis target probe was dissolved in the hybridization solution and hybridized with the hybrid bead prepared in Example 8-1. After the reaction was carried out at 95°C for 5 minutes and at 40°C for 30 minutes. Thereafter, after the reaction was terminated, the reactant
25 was transferred to a 96-well filter plate, and washed with

the washing buffer three times. After washing, the resultant was agitated in 100 μ l of 500-fold diluted solution of streptavidin-phycoerythrin (SigmaAldirich, S3402) for 15 minutes in the dark.

5 The bead for each well was read in a Luminex 100 instrument using the hybrid bead sample prepared as described above. The Luminex 100 instrument used two lasers: one indicated a bead number, and the other calculated an amount of reacted phycoerythrin to indicate
10 the calculated amount as a numerical value. An amount of the target probe binding to each of the capture probe may be determined as a mean fluorescence index (MFI) value while scanning the corresponding bead.

15 Example 9. Analysis of Serum Proteins of Cardiovascular Disease Patient

It was possible to confirm a profile of serum proteins in the human serum using the nucleic acid chip based on the target single-stranded nucleic acids binding to the human
20 serum proteins from the results of FIG. 6, and it may be confirmed that profiles of biomolecules in serums of a healthy person A and a cardiovascular disease patient (B) with stable angina pectoris were different from each other.

FIG. 7 is a flow chart showing a sequence of a process
25 of constructing a database of the profiles obtained from

blood biosamples of patients using the nucleic chip of the present invention according to disease type. FIG. 8 is a flow chart showing a process of generating a profile of biomolecules for a serum of a specific person to diagnose a disease using database constructed from the generated profiles according to disease type and a program using an artificial neural network.

As shown in FIG. 8, database constructed with the profiled generated from various biosamples may be analyzed using bioinformatics technologies, thereby making it possible to secure useful information.

Clinical data of the serum biosamples used to construct databases for diagnosing cardiovascular diseases are summarized in the following Table 2, and the samples were obtained from a total of 127 persons including 37 healthy persons, 36 stable angina pectoris patients, 28 unstable angina pectoris patients, and 27 myocardial infarction patients. A serum sample from the person named Lee 2-1 (99) was assayed using the serum profile databases of healthy persons and patients with cardiovascular diseases including stable angina pectoris, unstable angina pectoris, and myocardial infarction, and the results are shown in FIG. 9. The subject may be predicted to be healthy with 10-fold cross validation accuracy of 72.5 %.

[Table 2]

Clinical Information of Cardiovascular Disease Patients

	Healthy Person	Stable Angina Pectoris	Unstable Angina Pectoris	Myocardial Infarction
Gender				
Male	35	35	27	27
Female	2	1	1	0
Age				
40 ~ 49	1	0	1	0
50 ~ 59	13	17	15	17
60 ~ 69	22	18	11	10
70 ~ 79	1	1	1	0
Total	37	36	28	27

Clinical data of the serum samples used to construct databases for diagnosing liver cancer are summarized in the following Table 3, and the samples were obtained from a total of 102 persons including 19 healthy persons and 83 liver cancer patients, of which 72 were non-metastatic liver cancer patients and 11 were metastatic liver cancer patients.

After constructing a patient model of liver cancer patients and healthy persons from the database of profiles of serum proteins of liver cancer patients and healthy persons, a patient model of metastatic liver cancer patients and non-metastatic liver cancer patients was constructed from the database of the liver cancer patients.

First, whether or not a blind patient is a liver cancer patient may be determined using the patient model of the liver cancer patients and the healthy persons and a program using the artificial neural network, and

continuously, a metastatic stage, a liver cancer progression stage, may be additionally confirmed in a benign liver cancer patient using the patient model of the metastatic patients and the non-metastatic patients and the
 5 program using the artificial neural network. In addition, prognosis, drug-responsibility, and the like, as well as a progression state of a disease such as the metastatic state, and the like, may also be examined.

A serum sample from the person named Kim was assayed
 10 using the serum profile databases of healthy persons and liver cancer patients, and the results are shown in FIG. 10. The subject may be predicted to be a liver cancer patient with 10-fold cross validation accuracy of 93.0 %.

To determine whether or not the cancer underwent
 15 metastasis, the serum sample (of Kim) was further assayed using serum profile databases of healthy persons, and metastatic and non-metastatic liver cancer patients. As a result, the subject may be predicted to be a non-metastatic liver cancer patient with 10-fold cross validation accuracy
 20 of 76 %.

[Table 3]

Clinical Information of Liver Cancer Patients

	Healthy Person	Non-Metastatic Liver Cancer	Metastatic Liver Cancer
Gender			
Male	17	67	11
Female	2	5	0
Age			
40 ~ 49	14	60	7

50 ~ 59	5	7	3
60 ~ 69	0	5	1
Total	19	72	11

FIG. 11 is a flow chart showing a sequence of a process of comparing serum profiles between healthy persons and cardiovascular patients to determine spots peculiar to the cardiovascular disease patients, attaching biotin to single-stranded nucleic acids corresponding thereto, sequentially reacting with the single-stranded nucleic acids with streptavidin and the serum biosample, separating the resulting complexes, and separating bands formed by electrophoresis, and then identifying biomolecules. FIG. 12 is a view showing determination of an amino acid sequence of the protein bound to the selected single-stranded nucleic acid using a MALDI-TOF-TOF instrument.

Profiles of biomolecules of a specific biosample were searched and analyzed using the nucleic acid chip according to the present invention, onto which single-stranded nucleic acids based on the single-stranded nucleic acids binding to biomolecules configuring the biosample were affixed.

Further, after producing medicinally useful biomolecules of a biosample to construct a database, a serum profile of a specific person was generated and assayed with a program produced using an artificial neural

network algorithm, thereby determining whether the person is afflicted or not with a cardiovascular disease or liver cancer and, if so afflicted, to determine what the cardiovascular disease is or whether or not the liver
5 cancer has metastasized.

Useful spots were determined by comparison with databases constructed according to the disease type, and single-stranded nucleic acids corresponding to the spots were prepared, thereby separating and identifying proteins
10 corresponding thereto.

Example 10. Generation and Application of Profile of Surface Biomolecules of Cell Lines

10-1. Preparation of Biochip (Nucleic Acid Chip)

15 In the present invention, a biosample composed of two or more biomolecules was an example of cell lines.

A biochip for generating profiles of surface biomolecules of a non-small cell lung cancer cell line (biosample), according to the present invention, was
20 prepared by the methods described in Examples 2 to 4. After reacting prepared random single-stranded nucleic acids with the lung cancer cell line, repetitively, cell line (biomolecule)-single-stranded nucleic acid complexes were washed with a washing buffer to dissociate unbound
25 single-stranded nucleic acids and single-stranded nucleic

acids depending on binding intensity thereof, and centrifuged at 5,000×g. Then, the cell line-single-stranded nucleic acid complexes were separated by centrifugation, thereby preparing single-stranded nucleic acids binding to the non-small cell lung cancer cell line.

Clones were selected from the prepared single-stranded nucleic acids, base sequenced, and analyzed, thereby selecting about 1,000 single-stranded nucleic acids. Capture probes having base sequences complementary to the selected about 1000 single-stranded nucleic acids were synthesized by the method of Example 2, and attached to a solid supporter, thereby preparing the nucleic acid chip according to the present invention.

10-2. Generation of Profile of Surface Biomolecules of Cell Line

A profile of surface biomolecules of a small cell lung cancer (SCLC) cell line was generated using the nucleic acid chip prepared by the method of Example 4. After reacting the small cell lung cancer cell line with a pool of single-stranded nucleic acids, biomolecule-single-stranded nucleic acid complexes of the cell line (biosample) were washed and separated. The single-stranded nucleic acids binding to the complexes were amplified and labeled by the method of Example 3. Capture probes and the

labeled target probes were reacted with each other by the method of Example 4. A labeled substance bound to the target probes was measured by the method of Example 5, and a profile of surface biomolecules of the non-small cell lung cancer cell line was confirmed.

Fluorescent images obtained by selecting single-stranded nucleic acids estimated to strongly bind to the small cell lung cancer (SCLC) cell line using the generated profile, synthesizing FITC-attached single-stranded nucleic acids, and reacting the synthesized FITC-attached single-stranded nucleic acids with the small cell lung cancer cell line, the non-small cell lung cancers (NSCLC) cell line, and blood cancer cell lines (MRC-5 and THP-1) are shown in FIG. 13.

As described above, it may be confirmed that the single-stranded nucleic acids selected by analyzing the profile of the small cell lung cancer cell line generated using the nucleic acid chip according to the present invention bound to the small cell lung cancer cell line.

20

Example 11. Generation and Application of Profile of Surface Biomolecules of E. coli

11-1. Preparation of Biochip (Nucleic Acid Chip)

A nucleic acid chip according to the present invention was prepared using E. coli KCTC12006 (biosample) by the

methods of Examples 2 to 4. After reacting prepared single-stranded nucleic acids with E. coli, repetitively, E. coli (biomolecule)-single-stranded nucleic acid complexes were washed with a washing buffer to dissociate unbound
5 single-stranded nucleic acids and single-stranded nucleic acids depending on binding intensity thereof, and centrifuged at 5,000×g. Then, the E. coli-single-stranded nucleic acid complexes were separated by centrifugation, thereby preparing single-stranded nucleic acids binding to
10 surface biomolecules of E. coli.

Clones were selected from the prepared single-stranded nucleic acids, base sequenced, and analyzed, thereby selecting about 1,000 single-stranded nucleic acids. Capture probes having base sequences complementary to the
15 selected about 1000 single-stranded nucleic acids were synthesized and attached to a solid supporter, thereby preparing the nucleic acid chip according to the present invention.

20 11-2. Generation of Profile of Surface Biomolecules of E. coli

In the present invention, a biosample composed of two or more biomolecules was an example of bacteria.

A profile of surface biomolecules of E. coli KCTC12006
25 was generated using the nucleic acid chip prepared by the

method of Example 6.

After reacting *E. coli* with a pool of single-stranded nucleic acids, *E. coli*-target single-stranded nucleic acid complexes were washed and separated. The single-stranded
5 nucleic acids binding to the complexes were amplified and labeled by the method of Example 3. Capture probes and the labeled target probes were reacted with each other by the method of Example 4. The label substance bound to the target single-stranded nucleic acids was measured by the
10 method of Example 5, and a profile of surface biomolecules of *E. coli* was confirmed.

A profile of surface biomolecules of *Salmonella typhimurium* ATCC13311 was obtained by the same method as that used to generate the profile of the surface
15 biomolecules of *E. coli*, thereby constructing a database therefor. Then, single-stranded nucleic acids specifically binding to *E. coli* were selected using a hierarchical clustering method. Specificity of the single-stranded nucleic acids was analyzed using an SPR device (BIAcore),
20 and the results are shown in FIG. 14. It was confirmed that the selected single-stranded nucleic acids were specifically bound to *E. coli* as compared to *Salmonella typhimurium*.

The presence or absence of *E. coli* in a solution and a
25 degree of contamination in food by *E. coli* were measured

using the selected single-stranded nucleic acids by a method for measuring E. coli using single-stranded nucleic acids and gold nano-particles (e.g., see Korean Patent Application No. 10-2006-0072480), and the results are shown
5 in FIG. 15. It was confirmed that in the case of reacting the single-stranded nucleic acids with a SELEX buffer with which the food had been washed, adding the gold nano-particles thereto, and adding a NaCl solution thereto, when there was no E. coli, a color of the solution was pale
10 transparent blue, but when the solution was contaminated with E. coli, the color of the solution was changed to red. In addition, it was confirmed that the color intensity was proportional to the quantity of E. coli.

15 The exemplary embodiment of the present invention has been described above. Those skilled in the art will appreciate that the present invention may be implemented in a modified shape, without departing from the scope and spirit of the invention as disclosed in the accompanying
20 claim. Therefore, the Examples described above should be considered in view of illustration rather than limitation. It should be interpreted that the scope of the present invention is defined by the following claims rather than the above-mentioned detailed description and all of
25 differences within a scope equivalent thereto are included

in the appended claims of the present invention.

Although the preferred embodiments of the present invention have been disclosed for illustrative purposes, those skilled in the art will appreciate that various modifications, additions and substitutions are possible, without departing from the scope and spirit of the invention as disclosed in the accompanying claims.

CLAIMS

1. A method for preparing a biochip using a reference substance, the method comprising:

5 selecting a substance for quality control and determining the selected substance as the reference substance;

determining ligands binding to biomolecules contained in a biosample composed of two or more biomolecules and/or the reference substance;

10 synthesizing capture probes using information on the determined ligands and affixing the synthesized capture probes onto a substrate; and

collecting binding information between the biomolecules in the biosample and the ligands using target probes prepared
15 from the reference substance and the biomolecules contained in the biosample to be analyzed, the reference substance and the biomolecules being used to select the ligands for analyzing biological significance of the biomolecules.

20 2. The method of claim 1, wherein the substance is not contained in the biosample to be analyzed.

3. The method of claim 1, wherein the ligands binding to the biomolecules and the reference substance are selected
25 from the group consisting of antibodies, peptides, single-

stranded nucleic acids, and aptamers.

4. The method of claim 1, wherein the determining of the biomolecule-binding ligands binding to the biomolecules
5 contained in the biosample includes:

reacting random single-stranded nucleic acids with the biomolecules to prepare biomolecule-single-stranded nucleic acid complexes;

washing the biomolecule-single-stranded nucleic acid
10 complexes, measuring binding affinities between the biomolecules and the single-stranded nucleic acids, and selecting the biomolecule-single-stranded nucleic acid complexes having a binding affinity above a predetermined level;

15 separating single-stranded nucleic acids from the selected complexes and amplifying the separated single-stranded nucleic acids; and

determining base sequences of the amplified single-stranded nucleic acids to determine the biomolecule-binding
20 single-stranded nucleic acids.

5. The method of claim 1, wherein the selecting of the ligands for analyzing significance of the biomolecules includes:

25 reacting the biosample and biomolecule-binding single-

stranded nucleic acids to form a single-stranded nucleic acid complex and separating the complex;

amplifying and labeling the single-stranded nucleic acid in the separated biomolecule-single-stranded nucleic acid complex to prepare an analysis target probe; and

obtaining binding profiles of the capture probes in the biochip using the labeled analysis target probe as a target probe.

10 6. The method of claim 1, wherein in the synthesizing of the capture probes, the capture probes are synthesized using base sequences selected from the group consisting of base sequences of biomolecule-binding single-stranded nucleic acids and single-stranded nucleic acids binding to the
15 reference substances, and base sequences complementary thereto.

7. The method of claim 1, wherein the target probe is prepared by preparing analysis target probes from a biosample
20 to which different amounts of external molecules configuring the reference substance are added, or preparing analysis target probes to which different amounts of analysis marker target probes binding to capture probes corresponding to the external molecules configuring the reference substance are
25 added, and adding comparison target probes binding to the

capture probes to the analysis target probes.

8. A method for selecting a biomolecule analysis single-stranded nucleic acid, the method comprising:

5 preparing a biochip onto which capture probes synthesized using information on ligands binding to biomolecules contained in a biosample and ligands binding to molecules configuring a reference substance are affixed;

obtaining binding profiles of the biosample, analyzed
10 using target probes prepared from ligands binding to biomolecules and ligands binding to external molecules configuring the reference substance and the biochip; and

comparing the obtained binding information with pre-secured data on binding information to analyze biological
15 significance of unknown biomolecules.

9. The method of claim 8, wherein the biosample is selected from the group consisting of bacteria, fungi, viruses, cell lines, and tissue, and the biomolecule is at
20 least one or more selected from the group consisting of proteins, carbohydrates, lipids, polysaccharides, glycoproteins, hormones, receptors, antigens, antibodies, and enzymes.

25 10. A method for selecting a biomolecule analysis

single-stranded nucleic acid, wherein a quality control reference substance for analyzing a binding single-stranded nucleic acid binding to biomolecules in a biosample composed of two or more biomolecules and an analysis single-stranded
5 nucleic acid is used, and the binding single-stranded nucleic acid is selected from a nucleic acid library composed of random single-stranded nucleic acids having random base sequences, whereby internal quality control is performed by analyzing a quality control single-stranded nucleic acid using
10 a nucleic acid analysis method.

11. The method for selecting a biomolecule analysis single-stranded nucleic acid of claim 10, wherein the quality control reference substance is a biomolecule that is not
15 contained in the biosample to be analyzed.

12. The method for selecting a biomolecule analysis single-stranded nucleic acid of claim 11, wherein the method comprises:

20 preparing the quality control single-stranded nucleic acid from the reference substances;

preparing the binding single-stranded nucleic acids from the biomolecules in the biosample; and

preparing a supporter onto which a capture probe
25 synthesized using base sequences of the quality control

single-stranded nucleic acid and the binding single-stranded nucleic acid is affixed, and

a biosample, a reference substance, a binding single-stranded nucleic acid, a quality control single-stranded nucleic acid, and a nucleic acid chip, for selecting the analysis single-stranded nucleic acid for analyzing biological significance of biomolecules, are used to generate binding profiles between the biomolecules and the binding single-stranded nucleic acids.

10

13. The method for selecting a biomolecule analysis single-stranded nucleic acid of claim 12, wherein the preparing of the binding single-stranded nucleic acids includes:

15 reacting single-stranded nucleic acids having random base sequences with a sample composed of the biomolecules in the biosample and the reference substance to select biomolecule-single-stranded nucleic acid complexes;

separating single-stranded nucleic acids from the complexes and amplifying the separated single-stranded nucleic acids to prepare single-stranded DNAs; and

preparing the binding single-stranded nucleic acids by determining base sequences of the single-stranded DNAs.

25 14. The method for selecting a biomolecule analysis

single-stranded nucleic acid of claim 13, wherein in the selecting of the biomolecule-single-stranded nucleic acid complexes, the biomolecule-single-stranded nucleic acid complexes in a reaction solution are washed, binding
5 affinities between the biomolecules and the single-stranded nucleic acids are measured, and the biomolecule-single-stranded nucleic acid complexes having a binding affinity above a predetermined level are selected.

10 15. The method for selecting a biomolecule analysis single-stranded nucleic acid of claim 14, wherein in the selecting of the biomolecule-single-stranded nucleic acid complexes, the biomolecule-single-stranded nucleic acid complexes are selected by performing capillary electrophoresis
15 on the reaction solution, or treating the reaction solution with a structure of nitrocellulose and nylon.

16. The method for selecting a biomolecule analysis single-stranded nucleic acid of claim 12, wherein the
20 supporter onto which the capture probe is affixed is selected from the group consisting of a glass slide, a sensing surface of a bio sensor, beads, and nanoparticles.

17. The method for selecting a biomolecule analysis
25 single-stranded nucleic acid of claim 12, wherein the capture

probe is synthesized using at least one base sequence selected from the base sequences of the binding single-stranded nucleic acid and the quality control single-stranded nucleic acid, and the base sequences complementary thereto.

5

18. The method for selecting a biomolecule analysis single-stranded nucleic acid of claim 12, wherein the generating of the binding profiles between the biomolecules in the biosample and the binding single-stranded nucleic acids
10 includes:

preparing analysis target probes containing a labeling substance from the reference substance, the biosample, the quality control single-stranded nucleic acid, and the binding single-stranded nucleic acids;

15 preparing comparison target probes containing a labeling substance by mixing and amplifying the binding single-stranded nucleic acids corresponding to the capture probes and the quality control single-stranded nucleic acid;

preparing target probes by mixing the analysis target
20 probes and the comparison target probes with each other; and

generating the binding profiles by performing a hybridization reaction between the target probes and the capture probes on the supporter.

25 19. The method for selecting a biomolecule analysis

single-stranded nucleic acid of claim 18, wherein the preparing of the analysis target probes includes:

preparing an analysis sample obtained by adding a reference substance I composed of different amounts of
5 reference substances to the biosample;

separating biomolecule-single-stranded nucleic acid complexes and reference substance-single-stranded nucleic acid complexes formed by reacting the analysis sample with the single-stranded nucleic acids composed of the binding single-
10 stranded nucleic acids and the quality control single-stranded nucleic acid; and

preparing the analysis target probes by separating the single-stranded nucleic acids from the separated complexes and amplifying and labeling the separated single-stranded nucleic
15 acids.

20. The method for selecting a biomolecule analysis single-stranded nucleic acid of claim 18, wherein the preparing of the analysis target probes includes:

20 separating single-stranded nucleic acids from the biomolecule-single-stranded nucleic acid complexes formed by reacting the biosample with the binding single-stranded nucleic acids; and

preparing the analysis target probes by mixing a
25 reference substance II composed of different amounts of

quality control single-stranded nucleic acids with the separated single-stranded nucleic acids and performing amplification and labeling thereon.

5 21. A method for preparing a biochip using a reference substance, the method comprising analyzing two or more biomolecules in a biosample composed two or more biomolecules using the reference substance and an analysis single-stranded nucleic acid.

10

22. A method for analyzing biomolecules, the method comprising performing internal quality control using a quality control reference substance for analyzing biomolecules in a biosample using an analysis single-stranded nucleic acid by
15 analyzing a single-stranded nucleic acid for the quality control reference substance using a nucleic acid analysis method.

23. The method of claim 22, wherein analysis of the
20 biomolecules in the biosample using the analysis single-stranded nucleic acid is performed by the nucleic acid analysis method.

24. The method of claim 22, wherein the quality control
25 reference substance is a biomolecule that is not contained in

the biosample to be analyzed.

25. The method of claim 22, wherein the method comprises:

5 affixing capture probes synthesized using base sequences of the analysis single-stranded nucleic acid and the quality control single-stranded nucleic acid onto a supporter;

 preparing target probes containing a labeling substance from the reference substance, the biosample, the quality control single-stranded nucleic acid, and the analysis single-stranded nucleic acid;

 obtaining binding information by performing a hybridization reaction between the target probes and the capture probes on the supporter; and

15 comparing the obtained binding information with pre-secured data on binding information to analyze biological significance of the biomolecules.

26. The method of claim 25, wherein the preparing of the target probes includes:

 preparing analysis target probes containing a labeling substance from the reference substance, the biosample, the quality control single-stranded nucleic acid, and the analysis single-stranded nucleic acid;

25 preparing mixing and amplifying the analysis single-

stranded nucleic acid corresponding to the capture probe and the quality control single-stranded nucleic acid to prepare comparison target probes containing a labeling substance; and preparing target probes composed of the analysis target probes and the comparison target probes.

27. The method of claim 25, wherein the supporter onto which the capture probes are affixed is selected from a glass slide, a sensing surface of a bio sensor, beads, nanoparticles, and the like.

28. The method of claim 25, wherein the capture probe has a base sequence forming completely complementary binding with base sequences of the analysis single-stranded nucleic acid and the quality control single-stranded nucleic acid.

29. The method of claim 25, wherein a primer containing a labeling substance, for labeling and amplifying single-stranded nucleic acids separated from the biomolecule-single-stranded nucleic acid complex and the reference substance-single-stranded nucleic acid complex is used.

30. The method of claim 25, wherein the preparing of the analysis target probe includes:

preparing an analysis sample by adding a reference

substance I composed of different amounts of reference substances to the biosample;

separating biomolecule-single-stranded nucleic acid complexes and reference substance-single-stranded nucleic acid complexes formed by reacting the analysis sample with single-
5 stranded nucleic acids composed of the analysis single-stranded nucleic acids and the quality control single-stranded nucleic acid; and

preparing the analysis target probe by separating the
10 analysis single-stranded nucleic acids from the separated complexes and amplifying and labeling the separated analysis single-stranded nucleic acids.

31. The method of claim 25, wherein the preparing of the
15 analysis target probe includes:

separating biomolecule-single-stranded nucleic acid complexes formed by reacting the biosample with the analysis single-stranded nucleic acids; and

preparing the labeled analysis target probe by mixing a
20 reference substance II composed of different amounts of quality control single-stranded nucleic acids with the analysis single-stranded nucleic acids separated from the separated biomolecule-single-stranded nucleic acid complexes and performing amplification and labeling thereon.

32. The method of claim 31, wherein in the separating of the biomolecule-single-stranded nucleic acid complexes, the biomolecule-single-stranded nucleic acid complexes are selected by performing capillary electrophoresis on a reaction
 5 solution, or treating the reaction solution with a structure of nitrocellulose and nylon.

33. The method of claim 25, wherein as the labeling substance, a fluorescent pigment selected from biotin, Cy2,
 10 GFP, YO-PRO-1, YOYO-1, Calcein, FITC, FlourX, ALEXA 488, Rhodamine 110, ABI 5-FAM, Oregon Green 500, Oregon green 488, RiboGreen, Rhodamine Green, Rhodamine 123, Magnesium Green, Calcium Green, TO-PRO-1, TOTO-1, ABI JOE, BODIPY 530/550, DiI, BODIPY TMR, BODIPY558/568, BODIPY564/570, Alexa 546, TRITC,
 15 Magnesium Orange, Phycoerythrin R & B, Rhodamine Phalloidin, Calcium Orange, Pyronin Y, Rhodamine B, ABI TAMRA, Rhodamine Red, Cy3.5, ABI ROX, Calcium Crimson, Alexa 594, Texas Red, Nile Red, YO-PRO-3, YOYO-3, R-phycocyanin, C-phycocyanin, TOPRO-3, TOTO-3, DiD DiI(5), Thiadicarbocyanine, Cy5.5, Cy5,
 20 and Cy3 is used.

34. The method of claim 22, further comprising:
 receiving data on binding information between the biomolecules and the analysis single-stranded nucleic acids in
 25 a patient group and binding information between the

biomolecules and the analysis single-stranded nucleic acids in
a control group to construct databases, the binding
information being generated by the method for analyzing
biomolecules including performing internal quality control
5 using the quality control reference substance for analyzing
the biomolecules in the biosample using the analysis single-
stranded nucleic acid by analyzing the single-stranded nucleic
acid for the quality control reference substance using a
nucleic acid analysis method;

10 performing pre-processing in an analysis system using the
received data on the binding information;

generating a patient model using the pre-processed
result;

loading the generated model and applying the loaded model
15 to a visiting patient to perform diagnosis corresponding to
blind test; and

evaluating performance of the system through cross
validation.

20 35. The method of claim 34, wherein a method for
selecting the patient model is selected from the group
consisting of linear model methods, support vector machine
methods, neural network methods, classification and regression
tree methods, ensemble learning methods, discriminant analysis
25 methods, a nearest neighbor method, Bayesian network methods,

and independent components analysis methods.

36. An apparatus for analyzing biomolecules, the apparatus comprising an apparatus for analyzing nucleic acids
5 composed of a sample treating device for preparing biomolecules in a biosample and a module for preparing biomolecule-single-stranded nucleic acid complexes and analyzing single-stranded nucleic acids of the complexes.

10 37. The apparatus of claim 36, further comprising:
a module for receiving data on binding information between the biomolecules and analysis single-stranded nucleic acids in a patient group and binding information between the biomolecules and the analysis single-stranded nucleic acids in
15 a control group to construct databases;
a module for performing pre-processing in an analysis system using the received data on binding information;
a module for generating a patient model using the pre-processed result;
20 a module for loading the generated model and applying the loaded model to a visiting patient to perform diagnosis corresponding to a blind test; and
a module for evaluating performance of the system through cross validation.

25

38. The apparatus of claim 37, wherein a method for selecting the patient model is selected from the group consisting of linear model methods, support vector machine methods, neural network methods, classification and regression
5 tree methods, ensemble learning methods, discriminant analysis methods, a nearest neighbor method, Bayesian network methods, and independent components analysis methods.

39. The apparatus of claim 36, wherein the biosample is
10 selected from the group consisting of bacteria, fungi, viruses, cell lines, and tissue, and the biomolecule is at least one selected from the group consisting of proteins, carbohydrates, lipids, polysaccharides, glycoproteins, hormones, receptors, antigens, antibodies, and enzymes.

15

40. The apparatus of claim 37, further comprising:
primarily confirming a disease of the patient using the generated patient model; and

continuously confirming a disease progression stage of
20 the patient, prognosis, and drug responsibility.

41. The apparatus of claim 40, wherein the patient model is a liver cancer patient model, the disease is liver cancer, and the confirming of the disease progression stage is
25 confirming metastasis.

42. A method for analyzing biomolecules, the method comprising:

reacting biomolecule analysis single-stranded nucleic
5 acids with two or more biomolecules in a biosample composed of
two or more biomolecules to form biomolecule-single-stranded
nucleic acid complexes;

performing electrophoresis on a reaction solution to
select the biomolecule-single-stranded nucleic acid complexes,
10 or treating the reaction solution with a structure made of
nitrocellulose and nylon to select the biomolecule-single-
stranded nucleic acid complexes; and

analyzing the analysis single-stranded nucleic acids of
the selected biomolecule-single-stranded nucleic acid
15 complexes using a nucleic acid analysis method.

43. A method for analyzing biomolecules, the method comprising:

receiving data on binding information between the
20 biomolecules and analysis single-stranded nucleic acids in a
patient group and binding information between the biomolecules
and the analysis single-stranded nucleic acids in a control
group to construct databases, the binding information being
generated by a method for analyzing biomolecules including
25 performing internal quality control using a quality control

reference substance for analyzing the biomolecules in a
biosample using the analysis single-stranded nucleic acids by
analyzing the single-stranded nucleic acid for the quality
control reference substance using a nucleic acid analysis
5 method;

performing pre-processing in an analysis system using the
received data on the binding information;

generating a patient model using the pre-processed
result;

10 loading the generated model and applying the loaded model
to a visiting patient to perform diagnosis corresponding to
blind test; and

evaluating performance of the system through cross
validation.

15

44. The method of claim 43, further comprising:

primarily confirming a disease of the patient using the
generated patient model; and

continuously confirming a disease progression stage of
20 the patient, prognosis, and drug responsibility.

45. The method of claim 44, wherein the patient model is
a liver cancer patient model, the disease is liver cancer, and
the confirming of the disease progression stage is confirming
25 a metastasis.

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6

A B C D E




Figure 7




Figure 8




Figure 9




Figure 10




Figure 11




Figure 12




Figure 13




Figure 14




Figure 15







Figure 16







AA ... Blood collection

BB ... Scanner interface (interlocked with OCS system)

CC ... AptacDSS DB Server / Store sample information of patient / Store analysis result of diagnosis engine

DD ... Disease analysis system / Diagnose and analyse diseases by using artificial intelligence (NN, DT, BN, SVM)

EE ... Diagnosis of doctor

FF ... Result output and analysis / Suggest various analysis results / Interlocked with OCS system